1
|
Svanøe AA, Humlevik ROC, Knutsvik G, Sæle AKM, Askeland C, Ingebriktsen LM, Hugaas U, Kvamme AB, Tegnander AF, Krüger K, Davidsen B, Hoivik EA, Aas T, Stefansson IM, Akslen LA, Wik E. Age-related phenotypes in breast cancer: A population-based study. Int J Cancer 2024; 154:2014-2024. [PMID: 38319154 DOI: 10.1002/ijc.34863] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2023] [Revised: 12/21/2023] [Accepted: 01/05/2024] [Indexed: 02/07/2024]
Abstract
Breast cancer in young (<40 years) is associated with a higher frequency of aggressive tumor types and poor prognosis. It remains unclear if there is an underlying age-related biology that contributes to the unfavorable outcome. We aim to investigate the relationship between age and breast cancer biology, with emphasis on proliferation. Clinico-pathologic information, immunohistochemical markers and follow-up data were obtained for all patients aged <50 (Bergen cohort-1; n = 355, not part of a breast screening program) and compared to previously obtained information on patients aged 50 to 69 years (Bergen cohort-2; n = 540), who participated in the Norwegian Breast Cancer Screening Program. Young breast cancer patients presented more aggressive tumor features such as hormone receptor negativity, HER2 positivity, lymph-node metastasis, the HER2-enriched and triple-negative subtypes and shorter survival. Age <40 was significantly associated with higher proliferation (by Ki67). Ki67 showed weaker prognostic value in young patients. We point to aggressive phenotypes and increased tumor cell proliferation in breast cancer of the young. Hence, tumors of young breast cancer patients may present unique biological features, also when accounting for screen/interval differences, that may open for new clinical opportunities, stratifying treatment by age.
Collapse
Affiliation(s)
- Amalie A Svanøe
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, Bergen, Norway
| | - Rasmus O C Humlevik
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, Bergen, Norway
- Department of Pathology, Haukeland University Hospital, Bergen, Norway
| | - Gøril Knutsvik
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, Bergen, Norway
- Department of Pathology, Haukeland University Hospital, Bergen, Norway
| | - Anna K M Sæle
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, Bergen, Norway
- Department of Pathology, Haukeland University Hospital, Bergen, Norway
| | - Cecilie Askeland
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, Bergen, Norway
- Department of Pathology, Haukeland University Hospital, Bergen, Norway
| | - Lise M Ingebriktsen
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, Bergen, Norway
| | - Ulrikke Hugaas
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, Bergen, Norway
| | - Amalie B Kvamme
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, Bergen, Norway
| | - Amalie F Tegnander
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, Bergen, Norway
| | - Kristi Krüger
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, Bergen, Norway
| | | | - Erling A Hoivik
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, Bergen, Norway
- Department of Pathology, Haukeland University Hospital, Bergen, Norway
| | - Turid Aas
- Department of Surgery, Haukeland University Hospital, Bergen, Norway
| | - Ingunn M Stefansson
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, Bergen, Norway
- Department of Pathology, Haukeland University Hospital, Bergen, Norway
| | - Lars A Akslen
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, Bergen, Norway
- Department of Pathology, Haukeland University Hospital, Bergen, Norway
| | - Elisabeth Wik
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, University of Bergen, Bergen, Norway
- Department of Pathology, Haukeland University Hospital, Bergen, Norway
| |
Collapse
|
2
|
Fiehn C, Leipe J, Weseloh C, Bergner R, Krüger K. Assessment of interactions and dosage recommendations of synthetic DMARDs-Evidence-based and consensus-based recommendations based on a systematic literature search. Z Rheumatol 2024; 83:8-19. [PMID: 37831190 DOI: 10.1007/s00393-023-01417-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/14/2023] [Indexed: 10/14/2023]
Abstract
Conventional synthetic (cs) and targeted synthetic (ts) disease-modifying antirheumatic drugs (DMARD) have potential interactions with a multitude of drugs. Furthermore, they sometimes have a lower therapeutic index, particularly in cases of limited organ functions. The aim of this work was to establish evidence-based recommendations on the therapeutic use of DMARDs in the context of drug interactions and dosage recommendations. A systematic literature search was carried out on the issue of drug interactions and dosages in cases of patients with limited kidney function and higher age and suffering from rheumatoid arthritis. A total of 2756 scientific publications were screened and 154 selected of which 68 were scrutinized in detail. Furthermore, the respective product information was also analyzed. A multitude of possible interactions of synthetic DMARDs with different drugs were detected, which were then assessed with respect to the clinical significance and consequences. A consensus process led to making recommendations with which the interactions were classified: A: dangerous combination, B: avoid combination (if possible, pausing DMARD treatment), C: possible combination requiring increased monitoring and potential adjustments in dosage and D: pharmacological interaction without relevance in DMARD standard doses. Apart from that dosage recommendations were established for each csDMARD and tsDMARD depending on kidney function and age. There are 3 primary recommendations and 11 core recommendations on interactions and dosages of csDMARDs and tsDMARDs meant as a practical help for therapeutic decision making and to improve safety in the treatment of rheumatoid arthritis.
Collapse
Affiliation(s)
- C Fiehn
- Kommission Pharmakotherapie, Deutsche Gesellschaft für Rheumatologie (DGRh), Berlin, Germany.
- Tätigkeitsschwerpunkt klinische Immunologie, Rheumatologie Baden-Baden, Beethovenstr. 2, 76530, Baden-Baden, Germany.
| | - J Leipe
- Kommission Pharmakotherapie, Deutsche Gesellschaft für Rheumatologie (DGRh), Berlin, Germany
- V. Medizinische Klinik, Universitätsmedizin Mannheim, Mannheim, Germany
| | - C Weseloh
- Kommission Pharmakotherapie, Deutsche Gesellschaft für Rheumatologie (DGRh), Berlin, Germany
- Deutsche Gesellschaft für Rheumatologie (DGRh), Berlin, Germany
| | - R Bergner
- Kommission Pharmakotherapie, Deutsche Gesellschaft für Rheumatologie (DGRh), Berlin, Germany
- Medizinische Klinik A, Klinikum Ludwigshafen, Ludwigshafen, Germany
| | - K Krüger
- Kommission Pharmakotherapie, Deutsche Gesellschaft für Rheumatologie (DGRh), Berlin, Germany
- Rheumatologisches Praxiszentrum St. Bonifatius, Munich, Germany
| |
Collapse
|
3
|
Hecksteden A, Hoppstädter J, Bizjak DA, Jerg A, Kirsten J, Krüger K, Niess A, Steinacker J, Kiemer AK. Effects of acute exercise and training status on glucocorticoid-induced leucine zipper (GILZ) expression in human skeletal muscle. J Sci Med Sport 2023; 26:707-710. [PMID: 37951824 DOI: 10.1016/j.jsams.2023.10.007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2023] [Revised: 10/02/2023] [Accepted: 10/12/2023] [Indexed: 11/14/2023]
Abstract
Interactions between statin therapy and physical exercise complicate effective cardiovascular prevention. Emerging evidence suggests that muscle strain related changes in the expression of the glucocorticoid-induced leucine zipper (GILZ) may be involved. Therefore, we measured GILZ mRNA expression levels in M. vastus lateralis samples of 32 healthy individuals before and after a standardized bout of strength or endurance exercise. Overall, we found a highly significant downregulation of GILZ after exercise training (p < 0.001). Within-subgroup changes were statistically significant only after strength training, supporting the role of muscle (as opposed to cardiocirculatory) strain. If confirmed, this may help fitting training recommendations and medication.
Collapse
Affiliation(s)
- A Hecksteden
- Universität Innsbruck, Institute of Sport Science, Austria; Medical University Innsbruck, Institute of Physiology, Austria.
| | - J Hoppstädter
- Saarland University, Department of Pharmacy, Chair of Pharmaceutical Biology, Germany
| | - D A Bizjak
- University of Ulm, Department of Internal Medicine, Division of Sports and Rehabilitation Medicine, Germany
| | - A Jerg
- University of Ulm, Department of Internal Medicine, Division of Sports and Rehabilitation Medicine, Germany
| | - J Kirsten
- University of Ulm, Department of Internal Medicine, Division of Sports and Rehabilitation Medicine, Germany
| | - K Krüger
- University of Giessen, Department of Exercise Physiology and Sports Therapy, Germany
| | - A Niess
- University Hospital Tübingen, Department of Sports Medicine, Germany
| | - J Steinacker
- University of Ulm, Department of Internal Medicine, Division of Sports and Rehabilitation Medicine, Germany
| | - A K Kiemer
- Saarland University, Department of Pharmacy, Chair of Pharmaceutical Biology, Germany
| |
Collapse
|
4
|
Tinwell H, Karmaus A, Gaskell V, Gomes C, Grant C, Holmes T, Jonas A, Kellum S, Krüger K, Malley L, Melching-Kollmuss S, Mercier O, Pandya H, Placke T, Settivari R, De Waen B. Evaluating H295R steroidogenesis assay data for robust interpretation. Regul Toxicol Pharmacol 2023; 143:105461. [PMID: 37490962 DOI: 10.1016/j.yrtph.2023.105461] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2023] [Revised: 06/22/2023] [Accepted: 07/21/2023] [Indexed: 07/27/2023]
Abstract
The in vitro H295R steroidogenesis assay (OECD TG 456) is used to determine a chemical's potential to interfere with steroid hormone synthesis/metabolism. As positive outcomes in this assay can trigger significant higher tiered testing, we compiled a stakeholder database of reference and test item H295R data to characterize assay outcomes. Information concerning whether a Level 5 reproductive toxicity study was triggered due to a positive outcome in the H295R assay was also included. Quality control acceptance criteria were not always achieved, suggesting this assay is challenging to conduct within the guideline specifications. Analysis of test item data demonstrated that pairwise significance testing to controls allowed for overly sensitive statistically significant positive outcomes, which likely contribute to the assay's high positive hit rate. Complementary interpretation criteria (e.g., 1.5-fold change threshold) markedly reduced the rate of equivocal and positive outcomes thus improving identification of robust positive effects in the assay. Finally, a case study (positive H295R outcome and no endocrine adversity in vivo) is presented, which suggests that stricter data interpretation criteria could refine necessary in vivo follow-up testing. Overall, the described additional criteria could improve H295R data interpretation and help inform on how to best leverage this assay for regulatory purposes.
Collapse
Affiliation(s)
- H Tinwell
- Bayer SAS, 16 Rue Jean-Marie Leclair, 69009, Lyon, France.
| | - A Karmaus
- Inotiv, 601 Keystone Park Drive, Morrisville, NC, 27560, United States
| | - V Gaskell
- Nufarm UK Ltd, Wyke Lane, Bradford, BD12 9EJ, UK
| | - C Gomes
- BASF SE, Experimental Toxicology and Ecology, Carl-Bosch-Strasse 38, 67056, Ludwigshafen, Germany
| | - C Grant
- Regulatory Science Associates, Kip Marina, Inverkip, Renfrewshire, PA16 OAS, UK
| | - T Holmes
- ADAMA Deutschland GmbH, Edmund-Rumpler-Str. 651149, Koeln (Cologne), Germany
| | - A Jonas
- Sumitomo Chemical Agro Europe, Parc D'Affaires de Crécy, 10A Rue de La Voie Lactée, 69370, Saint Didier Au Mont D'Or, France
| | - S Kellum
- Corteva Agriscience, Haskell R&D Center, 1090 Elkton Rd, Bldg 320, Newark, DE, 19711, USA
| | - K Krüger
- HELM AG, Nordkanalstrasse 28, 20097, Hamburg, Germany
| | - L Malley
- FMC, Stine Research Center, 1090 Elkton Road, Newark, DE, 19711, USA
| | | | - O Mercier
- Sumitomo Chemical Agro Europe, Parc D'Affaires de Crécy, 10A Rue de La Voie Lactée, 69370, Saint Didier Au Mont D'Or, France
| | - H Pandya
- UPL Limited, Mumbai, 400051, India
| | - T Placke
- Syngenta, Rosentalstrasse 67, CH-4058 Basel, Switzerland
| | - R Settivari
- Corteva Agriscience, Haskell R&D Center, 1090 Elkton Rd, Bldg 320, Newark, DE, 19711, USA
| | - B De Waen
- ISK, De Kleetlaan 12b, 1831, Machelen, Belgium
| |
Collapse
|
5
|
Abstract
Hyperplasia of the pharyngeal tonsils is to be considered pathologic when nasopharyngeal symptoms of mechanical obstruction and/or chronic inflammation occur. Chronic Eustachian tube dysfunction can result in various middle ear diseases such as conductive hearing loss, cholesteatoma, and recurrent acute otitis media. During examination, attention should be paid to the presence of adenoid facies (long face syndrome), with a permanently open mouth and visible tip of the tongue. In the case of severe symptoms and/or failure of conservative treatment, adenoidectomy is usually performed on an outpatient basis. Conventional curettage remains the established standard treatment in Germany. Histologic evaluation is indicated for clinical evidence of mucopolysaccharidoses. Due to the risk of hemorrhage, the preoperative bleeding questionnaire, which is obligatory before every pediatric surgery, is referred to. Recurrence of adenoids is possible despite correct adenoidectomy. Before discharge home, otorhinolaryngologic inspection of the nasopharynx for secondary bleeding should be performed and anesthesiologic clearance obtained.
Collapse
Affiliation(s)
- Z Ahmad
- Department of Otolaryngology-Head and Neck Surgery, Bundeswehr Hospital of Ulm, Oberer Eselsberg 40, 89081, Ulm, Germany.
| | - K Krüger
- Institute of General Medicine, Berlin Charité Hospital, Berlin, Germany
| | - J Lautermann
- Department of Otolaryngology-Head and Neck Surgery, Plastic Surgery, Martha-Maria Halle-Dölau Hospital, Halle-Dölau, Germany
| | - B Lippert
- Department of Otolaryngology-Head and Neck Surgery, Plastic Surgery, SLK-Kliniken Heilbronn GmbH am Gesundbrunnen, Heilbronn, Germany
| | - T Tenenbaum
- Department of Paediatric and Adolescent Medicine, Sana Klinikum Lichtenberg, Berlin, Germany
| | - M Tigges
- Department of Otolaryngology, Städtisches Klinikum Karlsruhe, Karlsruhe, Germany
| | - M Tisch
- Department of Otolaryngology-Head and Neck Surgery, Bundeswehr Hospital of Ulm, Oberer Eselsberg 40, 89081, Ulm, Germany
| |
Collapse
|
6
|
Ahmad Z, Krüger K, Lautermann J, Lippert B, Tenenbaum T, Tigges M, Tisch M. [Adenoids-diagnosis and treatment: the new German S2k guideline]. HNO 2023; 71:285-293. [PMID: 37071194 PMCID: PMC10125940 DOI: 10.1007/s00106-023-01298-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 03/10/2023] [Indexed: 04/19/2023]
Abstract
Hyperplasia of the pharyngeal tonsils is to be considered pathologic when nasopharyngeal symptoms of mechanical obstruction and/or chronic inflammation occur. Chronic Eustachian tube dysfunction can result in various middle ear diseases such as conductive hearing loss, cholesteatoma, and recurrent acute otitis media. During examination, attention should be paid to the presence of adenoid facies (long face syndrome), with a permanently open mouth and visible tip of the tongue. In the case of severe symptoms and/or failure of conservative treatment, adenoidectomy is usually performed on an outpatient basis. Conventional curettage remains the established standard treatment in Germany. Histologic evaluation is indicated for clinical evidence of mucopolysaccharidoses. Due to the risk of hemorrhage, the preoperative bleeding questionnaire, which is obligatory before every pediatric surgery, is referred to. Recurrence of adenoids is possible despite correct adenoidectomy. Before discharge home, otorhinolaryngologic inspection of the nasopharynx for secondary bleeding should be performed and anesthesiologic clearance obtained.
Collapse
Affiliation(s)
- Z Ahmad
- Klinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie, Bundeswehrkrankenhaus Ulm, Oberer Eselsberg 40, 89081, Ulm, Deutschland.
| | - K Krüger
- Institut für Allgemeinmedizin, Charité - Universitätsmedizin Berlin, Berlin, Deutschland
| | - J Lautermann
- Klinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie, Plastische Operationen, Krankenhaus Martha-Maria Halle-Dölau, Halle-Dölau, Deutschland
| | - B Lippert
- Klinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie, Plastische Operationen, SLK-Kliniken Heilbronn GmbH - Standort Gesundbrunnen, Heilbronn, Deutschland
| | - T Tenenbaum
- Klinik für Kinder- und Jugendmedizin, Sana Klinikum Lichtenberg, Berlin, Deutschland
| | - M Tigges
- Hals-Nasen-Ohrenklinik, Städtisches Klinikum Karlsruhe, Karlsruhe, Deutschland
| | - M Tisch
- Klinik für Hals-Nasen-Ohrenheilkunde, Kopf- und Halschirurgie, Bundeswehrkrankenhaus Ulm, Oberer Eselsberg 40, 89081, Ulm, Deutschland
| |
Collapse
|
7
|
Kiltz U, Buschhorn-Milberger V, Albrecht K, Lakomek HJ, Lorenz HM, Rudwaleit M, Schneider M, Schulze-Koops H, Aringer M, Hasenbring MI, Herzer P, von Hinüber U, Krüger K, Lauterbach A, Manger B, Oltman R, Schuch F, Schmale-Grede R, Späthling-Mestekemper S, Zinke S, Braun J. [Development of quality standards for patients with rheumatoid arthritis for use in Germany]. Z Rheumatol 2022; 81:744-759. [PMID: 34652486 PMCID: PMC9646547 DOI: 10.1007/s00393-021-01093-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/17/2021] [Indexed: 10/20/2022]
Abstract
Despite a qualitatively and structurally good care of patients with rheumatoid arthritis (RA) in Germany, there are still potentially amendable deficits in the quality of care. For this reason, the German Society for Rheumatology (DGRh) has therefore decided to ask a group of experts including various stakeholders to develop quality standards (QS) for the care of patients with RA in order to improve the quality of care. The QS are used to determine and quantitatively measure the quality of care, subject to relevance and feasibility. The recently published NICE and ASAS standards and a systematic literature search were used as the basis for development. A total of 8 QS, now published for the first time, were approved with the intention to measure and further optimize the quality of care for patients with RA in Germany.
Collapse
Affiliation(s)
- U Kiltz
- Rheumazentrum Ruhrgebiet, Claudiusstr. 45, 44649, Herne, Deutschland.
- Ruhr-Universität Bochum, Bochum, Deutschland.
| | | | - K Albrecht
- Programmbereich Epidemiologie, Deutsches Rheuma-Forschungszentrum (DRFZ), Berlin, Deutschland
| | - H-J Lakomek
- Johannes-Wesling-Klinikum Minden, Universitätsklinik für Geriatrie, Minden, Deutschland
| | - H-M Lorenz
- Sektion Rheumatologie, Medizinische Klinik V, Universitätsklinikum Heidelberg, Universität Heidelberg, Heidelberg, Deutschland
| | - M Rudwaleit
- Universitätsklinik für Innere Medizin und Rheumatologie, Klinikum Bielefeld Rosenhöhe, Universität Bielefeld, Bielefeld, Deutschland
| | - M Schneider
- Poliklinik, Funktionsbereich und Hiller Forschungszentrum für Rheumatologie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Deutschland
| | - H Schulze-Koops
- Sektion Rheumatologie und Klinische Immunologie, Medizinische Klinik und Poliklinik IV, LMU-Klinikum München, Ludwig-Maximilians-Universität München, München, Deutschland
| | - M Aringer
- Medizinische Klinik und Poliklinik III, Rheumatologie, Universitätsklinikum Carl Gustav Carus, Technische Universität Dresden, Dresden, Deutschland
| | - M I Hasenbring
- Abteilung für Medizinische Psychologie und Medizinische Soziologie, Ruhr-Universität Bochum, Bochum, Deutschland
| | - P Herzer
- Medicover München MVZ, München, Deutschland
| | - U von Hinüber
- Praxis für Rheumatologie und Osteologie, Hildesheim, Deutschland
| | - K Krüger
- Rheumatologisches Praxiszentrum St. Bonifatius, München, Deutschland
| | - A Lauterbach
- Physiotherapieschule Friedrichsheim, Friedrichsheim, Deutschland
| | - B Manger
- Medizinische Klinik 3 Rheumatologie und Immunologie, Universitätsklinikum, Friedrich-Alexander-Universität Erlangen/Nürnberg, Erlangen, Deutschland
| | - R Oltman
- Hochschule für Gesundheit Bochum, Bochum, Deutschland
| | - F Schuch
- Rheumatologische Schwerpunktpraxis Erlangen, Erlangen, Deutschland
| | | | | | - S Zinke
- Rheumatologische Schwerpunktpraxis Zinke, Berlin, Deutschland
- Bundesverband Deutscher Rheumatologen e. V. (BDRh), Grünwald, Deutschland
| | - J Braun
- Rheumazentrum Ruhrgebiet, Claudiusstr. 45, 44649, Herne, Deutschland
- Ruhr-Universität Bochum, Bochum, Deutschland
| |
Collapse
|
8
|
Krings O, Raabe S, Schumann B, Kamalakkannan S, Glahn F, Krüger K, Foth H. P07-23 C. elegans as a model to study the biological effects of anti-inflammatory drugs and their degradation products after UV-C irradiation under oxygen supply. Toxicol Lett 2022. [DOI: 10.1016/j.toxlet.2022.07.366] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
9
|
Andreev V, Arratia M, Baghdasaryan A, Baty A, Begzsuren K, Belousov A, Bolz A, Boudry V, Brandt G, Britzger D, Buniatyan A, Bystritskaya L, Campbell AJ, Cantun Avila KB, Cerny K, Chekelian V, Chen Z, Contreras JG, Cunqueiro Mendez L, Cvach J, Dainton JB, Daum K, Deshpande A, Diaconu C, Eckerlin G, Egli S, Elsen E, Favart L, Fedotov A, Feltesse J, Fleischer M, Fomenko A, Gal C, Gayler J, Goerlich L, Gogitidze N, Gouzevitch M, Grab C, Greenshaw T, Grindhammer G, Haidt D, Henderson RCW, Hessler J, Hladký J, Hoffmann D, Horisberger R, Hreus T, Huber F, Jacobs PM, Jacquet M, Janssen T, Jung AW, Jung H, Kapichine M, Katzy J, Kiesling C, Klein M, Kleinwort C, Klest HT, Kogler R, Kostka P, Kretzschmar J, Krücker D, Krüger K, Landon MPJ, Lange W, Laycock P, Lee SH, Levonian S, Li W, Lin J, Lipka K, List B, List J, Lobodzinski B, Malinovski E, Martyn HU, Maxfield SJ, Mehta A, Meyer AB, Meyer J, Mikocki S, Mondal MM, Morozov A, Müller K, Nachman B, Naumann T, Newman PR, Niebuhr C, Nowak G, Olsson JE, Ozerov D, Park S, Pascaud C, Patel GD, Perez E, Petrukhin A, Picuric I, Pitzl D, Polifka R, Preins S, Radescu V, Raicevic N, Ravdandorj T, Reimer P, Rizvi E, Robmann P, Roosen R, Rostovtsev A, Rotaru M, Sankey DPC, Sauter M, Sauvan E, Schmitt S, Schmookler BA, Schoeffel L, Schöning A, Sefkow F, Shushkevich S, Soloviev Y, Sopicki P, South D, Spaskov V, Specka A, Steder M, Stella B, Straumann U, Sun C, Sykora T, Thompson PD, Traynor D, Tseepeldorj B, Tu Z, Valkárová A, Vallée C, Van Mechelen P, Wegener D, Wünsch E, Žáček J, Zhang J, Zhang Z, Žlebčík R, Zohrabyan H, Zomer F. Measurement of Lepton-Jet Correlation in Deep-Inelastic Scattering with the H1 Detector Using Machine Learning for Unfolding. Phys Rev Lett 2022; 128:132002. [PMID: 35426724 DOI: 10.1103/physrevlett.128.132002] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/30/2021] [Revised: 12/20/2021] [Accepted: 02/25/2022] [Indexed: 06/14/2023]
Abstract
The first measurement of lepton-jet momentum imbalance and azimuthal correlation in lepton-proton scattering at high momentum transfer is presented. These data, taken with the H1 detector at HERA, are corrected for detector effects using an unbinned machine learning algorithm (multifold), which considers eight observables simultaneously in this first application. The unfolded cross sections are compared with calculations performed within the context of collinear or transverse-momentum-dependent factorization in quantum chromodynamics as well as Monte Carlo event generators.
Collapse
Affiliation(s)
- V Andreev
- Lebedev Physical Institute, Moscow, Russia
| | - M Arratia
- University of California, Riverside, California 92521, USA
| | | | - A Baty
- Rice University, Houston, Texas 77005-1827, USA
| | - K Begzsuren
- Institute of Physics and Technology of the Mongolian Academy of Sciences, Ulaanbaatar, Mongolia
| | - A Belousov
- Lebedev Physical Institute, Moscow, Russia
| | - A Bolz
- Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany
| | - V Boudry
- LLR, Ecole Polytechnique, CNRS/IN2P3, Palaiseau, France
| | - G Brandt
- II. Physikalisches Institut, Universität Göttingen, Göttingen, Germany
| | - D Britzger
- Max-Planck-Institut für Physik, München, Germany
| | - A Buniatyan
- School of Physics and Astronomy, University of Birmingham, Birmingham, United Kingdom
| | - L Bystritskaya
- Institute for Theoretical and Experimental Physics, Moscow, Russia
| | - A J Campbell
- Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany
| | - K B Cantun Avila
- Departamento de Fisica Aplicada, CINVESTAV, Mérida, Yucatán, México
| | - K Cerny
- Joint Laboratory of Optics, Palacký University, Olomouc, Czech Republic
| | - V Chekelian
- Max-Planck-Institut für Physik, München, Germany
| | - Z Chen
- Shandong University, Shandong, People's Republic of China
| | - J G Contreras
- Departamento de Fisica Aplicada, CINVESTAV, Mérida, Yucatán, México
| | | | - J Cvach
- Institute of Physics, Academy of Sciences of the Czech Republic, Praha, Czech Republic
| | - J B Dainton
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | - K Daum
- Fachbereich C, Universität Wuppertal, Wuppertal, Germany
| | - A Deshpande
- Stony Brook University, Stony Brook, New York 11794, USA
| | - C Diaconu
- Aix Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France
| | - G Eckerlin
- Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany
| | - S Egli
- Paul Scherrer Institut, Villigen, Switzerland
| | - E Elsen
- Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany
| | - L Favart
- Inter-University Institute for High Energies ULB-VUB, Brussels and Universiteit Antwerpen, Antwerp, Belgium
| | - A Fedotov
- Institute for Theoretical and Experimental Physics, Moscow, Russia
| | - J Feltesse
- Irfu/SPP, CE Saclay, Gif-sur-Yvette, France
| | - M Fleischer
- Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany
| | - A Fomenko
- Lebedev Physical Institute, Moscow, Russia
| | - C Gal
- Stony Brook University, Stony Brook, New York 11794, USA
| | - J Gayler
- Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany
| | - L Goerlich
- Institute of Nuclear Physics Polish Academy of Sciences, Krakow, Poland
| | | | - M Gouzevitch
- Université Claude Bernard Lyon 1, CNRS/IN2P3, Villeurbanne, France
| | - C Grab
- Institut für Teilchenphysik, ETH, Zürich, Switzerland
| | - T Greenshaw
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | | | - D Haidt
- Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany
| | - R C W Henderson
- Department of Physics, University of Lancaster, Lancaster, United Kingdom
| | - J Hessler
- Max-Planck-Institut für Physik, München, Germany
| | - J Hladký
- Institute of Physics, Academy of Sciences of the Czech Republic, Praha, Czech Republic
| | - D Hoffmann
- Aix Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France
| | | | - T Hreus
- Physik-Institut der Universität Zürich, Zürich, Switzerland
| | - F Huber
- Physikalisches Institut, Universität Heidelberg, Heidelberg, Germany
| | - P M Jacobs
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - M Jacquet
- IJCLab, Université Paris-Saclay, CNRS/IN2P3, Orsay, France
| | - T Janssen
- Inter-University Institute for High Energies ULB-VUB, Brussels and Universiteit Antwerpen, Antwerp, Belgium
| | - A W Jung
- Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana 47907, USA
| | - H Jung
- Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany
| | - M Kapichine
- Joint Institute for Nuclear Research, Dubna, Russia
| | - J Katzy
- Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany
| | - C Kiesling
- Max-Planck-Institut für Physik, München, Germany
| | - M Klein
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | - C Kleinwort
- Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany
| | - H T Klest
- Stony Brook University, Stony Brook, New York 11794, USA
| | - R Kogler
- Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany
| | - P Kostka
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | - J Kretzschmar
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | - D Krücker
- Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany
| | - K Krüger
- Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany
| | - M P J Landon
- School of Physics and Astronomy, Queen Mary, University of London, London, United Kingdom
| | - W Lange
- Deutsches Elektronen-Synchrotron DESY, Zeuthen, Germany
| | - P Laycock
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - S H Lee
- University of Michigan, Ann Arbor, Michigan 48109, USA
| | - S Levonian
- Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany
| | - W Li
- Rice University, Houston, Texas 77005-1827, USA
| | - J Lin
- Rice University, Houston, Texas 77005-1827, USA
| | - K Lipka
- Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany
| | - B List
- Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany
| | - J List
- Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany
| | | | | | - H-U Martyn
- I. Physikalisches Institut der RWTH, Aachen, Germany
| | - S J Maxfield
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | - A Mehta
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | - A B Meyer
- Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany
| | - J Meyer
- Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany
| | - S Mikocki
- Institute of Nuclear Physics Polish Academy of Sciences, Krakow, Poland
| | - M M Mondal
- Stony Brook University, Stony Brook, New York 11794, USA
| | - A Morozov
- Joint Institute for Nuclear Research, Dubna, Russia
| | - K Müller
- Physik-Institut der Universität Zürich, Zürich, Switzerland
| | - B Nachman
- Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - Th Naumann
- Deutsches Elektronen-Synchrotron DESY, Zeuthen, Germany
| | - P R Newman
- School of Physics and Astronomy, University of Birmingham, Birmingham, United Kingdom
| | - C Niebuhr
- Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany
| | - G Nowak
- Institute of Nuclear Physics Polish Academy of Sciences, Krakow, Poland
| | - J E Olsson
- Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany
| | - D Ozerov
- Paul Scherrer Institut, Villigen, Switzerland
| | - S Park
- Stony Brook University, Stony Brook, New York 11794, USA
| | - C Pascaud
- IJCLab, Université Paris-Saclay, CNRS/IN2P3, Orsay, France
| | - G D Patel
- Department of Physics, University of Liverpool, Liverpool, United Kingdom
| | | | - A Petrukhin
- Université Claude Bernard Lyon 1, CNRS/IN2P3, Villeurbanne, France
| | - I Picuric
- Faculty of Science, University of Montenegro, Podgorica, Montenegro
| | - D Pitzl
- Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany
| | - R Polifka
- Faculty of Mathematics and Physics, Charles University, Praha, Czech Republic
| | - S Preins
- University of California, Riverside, California 92521, USA
| | - V Radescu
- Department of Physics, Oxford University, Oxford, United Kingdom
| | - N Raicevic
- Faculty of Science, University of Montenegro, Podgorica, Montenegro
| | - T Ravdandorj
- Institute of Physics and Technology of the Mongolian Academy of Sciences, Ulaanbaatar, Mongolia
| | - P Reimer
- Institute of Physics, Academy of Sciences of the Czech Republic, Praha, Czech Republic
| | - E Rizvi
- School of Physics and Astronomy, Queen Mary, University of London, London, United Kingdom
| | - P Robmann
- Physik-Institut der Universität Zürich, Zürich, Switzerland
| | - R Roosen
- Inter-University Institute for High Energies ULB-VUB, Brussels and Universiteit Antwerpen, Antwerp, Belgium
| | - A Rostovtsev
- Institute for Information Transmission Problems RAS, Moscow, Russia
| | - M Rotaru
- Horia Hulubei National Institute for R&D in Physics and Nuclear Engineering (IFIN-HH), Bucharest, Romania
| | - D P C Sankey
- STFC, Rutherford Appleton Laboratory, Didcot, Oxfordshire, United Kingdom
| | - M Sauter
- Physikalisches Institut, Universität Heidelberg, Heidelberg, Germany
| | - E Sauvan
- LAPP, Université de Savoie, CNRS/IN2P3, Annecy-le-Vieux, France
- Aix Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France
| | - S Schmitt
- Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany
| | - B A Schmookler
- Stony Brook University, Stony Brook, New York 11794, USA
| | | | - A Schöning
- Physikalisches Institut, Universität Heidelberg, Heidelberg, Germany
| | - F Sefkow
- Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany
| | - S Shushkevich
- Lomonosov Moscow State University, Skobeltsyn Institute of Nuclear Physics, Moscow, Russia
| | - Y Soloviev
- Lebedev Physical Institute, Moscow, Russia
| | - P Sopicki
- Institute of Nuclear Physics Polish Academy of Sciences, Krakow, Poland
| | - D South
- Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany
| | - V Spaskov
- Joint Institute for Nuclear Research, Dubna, Russia
| | - A Specka
- LLR, Ecole Polytechnique, CNRS/IN2P3, Palaiseau, France
| | - M Steder
- Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany
| | - B Stella
- Dipartimento di Fisica Università di Roma Tre and INFN Roma 3, Roma, Italy
| | - U Straumann
- Physik-Institut der Universität Zürich, Zürich, Switzerland
| | - C Sun
- Shandong University, Shandong, People's Republic of China
| | - T Sykora
- Faculty of Mathematics and Physics, Charles University, Praha, Czech Republic
| | - P D Thompson
- School of Physics and Astronomy, University of Birmingham, Birmingham, United Kingdom
| | - D Traynor
- School of Physics and Astronomy, Queen Mary, University of London, London, United Kingdom
| | - B Tseepeldorj
- Institute of Physics and Technology of the Mongolian Academy of Sciences, Ulaanbaatar, Mongolia
- Ulaanbaatar University, Ulaanbaatar, Mongolia
| | - Z Tu
- Brookhaven National Laboratory, Upton, New York 11973, USA
| | - A Valkárová
- Faculty of Mathematics and Physics, Charles University, Praha, Czech Republic
| | - C Vallée
- Aix Marseille Univ, CNRS/IN2P3, CPPM, Marseille, France
| | - P Van Mechelen
- Inter-University Institute for High Energies ULB-VUB, Brussels and Universiteit Antwerpen, Antwerp, Belgium
| | - D Wegener
- Institut für Physik, TU Dortmund, Dortmund, Germany
| | - E Wünsch
- Deutsches Elektronen-Synchrotron DESY, Hamburg, Germany
| | - J Žáček
- Faculty of Mathematics and Physics, Charles University, Praha, Czech Republic
| | - J Zhang
- Shandong University, Shandong, People's Republic of China
| | - Z Zhang
- IJCLab, Université Paris-Saclay, CNRS/IN2P3, Orsay, France
| | - R Žlebčík
- Faculty of Mathematics and Physics, Charles University, Praha, Czech Republic
| | | | - F Zomer
- IJCLab, Université Paris-Saclay, CNRS/IN2P3, Orsay, France
| |
Collapse
|
10
|
Wernicke K, Grischke J, Stiesch M, Zeissler S, Krüger K, Bauer P, Hillebrecht A, Eberhard J. Influence of physical activity on periodontal health in patients with type 2 diabetes mellitus. A blinded, randomized, controlled trial. Clin Oral Investig 2021; 25:6101-6107. [PMID: 33796948 PMCID: PMC8531088 DOI: 10.1007/s00784-021-03908-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/28/2020] [Accepted: 03/23/2021] [Indexed: 11/30/2022]
Abstract
Objectives The aim was to investigate the effect of physical activity on periodontal health and HbA1c levels in patients with type 2 diabetes mellitus (T2DM) over a period of 6 months. Materials and methods Thirty-seven patients with non-insulin-dependent T2DM were included in the study. The intervention group (n=20) performed physical activity over a period of 6 months. The control group (n=17) did not receive any intervention. Baseline and final examinations included dental parameters and concentrations of glycosylated hemoglobin (HbA1c) and high-sensitivity C-reactive protein (hsCRP). Results Physical activity showed a positive effect on periodontal health. Both the BOP (p= 0.005) and the severity of periodontitis (p= 0.001) were significantly reduced in the intervention group compared to the control group. Furthermore, HbA1c levels were reduced (p= 0.010) significantly in the intervention group while hsCRP levels significantly increased in the control group (p= 0.04). Conclusions Within the limitations of this randomized, controlled trial, physical activity over a period of 6 months is a health-promoting measure for patients with T2DM and improves both periodontal health and HbA1c concentrations.
Collapse
Affiliation(s)
- K Wernicke
- Hannover Medical School, Hanover, Germany
| | - J Grischke
- Hannover Medical School, Hanover, Germany. .,Department of Prosthetic Dentistry and Biomedical Materials Science, Hannover Medical School, Carl-Neuberg-Str.1, 30625, Hannover, Germany.
| | - M Stiesch
- Hannover Medical School, Hanover, Germany
| | | | - K Krüger
- Justus-Liebig-Universität Gießen, Gießen, Germany
| | - P Bauer
- Justus-Liebig-Universität Gießen, Gießen, Germany
| | | | - J Eberhard
- The University of Sydney School of Dentistry and the Charles Perkins Centre, Faculty of Health and Medicine, The University of Sydney, Sydney, Australia
| |
Collapse
|
11
|
Krüger K, Silwal-Pandit L, Wik E, Straume O, Stefansson IM, Borgen E, Garred Ø, Naume B, Engebraaten O, Akslen LA. Baseline microvessel density predicts response to neoadjuvant bevacizumab treatment of locally advanced breast cancer. Sci Rep 2021; 11:3388. [PMID: 33564016 PMCID: PMC7873274 DOI: 10.1038/s41598-021-81914-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2020] [Accepted: 01/04/2021] [Indexed: 02/06/2023] Open
Abstract
A subset of breast cancer patients benefits from preoperative bevacizumab and chemotherapy, but validated predictive biomarkers are lacking. Here, we aimed to evaluate tissue-based angiogenesis markers for potential predictive value regarding response to neoadjuvant bevacizumab treatment in breast cancer. In this randomized 1:1 phase II clinical trial, 132 patients with large or locally advanced HER2-negative tumors received chemotherapy ± bevacizumab. Dual Factor VIII/Ki-67 immunohistochemical staining was performed on core needle biopsies at baseline and week 12. Microvessel density (MVD), proliferative microvessel density (pMVD; Factor VIII/Ki-67 co-expression), glomeruloid microvascular proliferation (GMP), and a gene expression angiogenesis signature score, were studied in relation to pathologic complete response (pCR), clinico-pathologic features and intrinsic molecular subtype. We found that high baseline MVD (by median) significantly predicted pCR in the bevacizumab-arm (odds ratio 4.9, P = 0.012). High pMVD, presence of GMP, and the angiogenesis signature score did not predict pCR, but were associated with basal-like (P ≤ 0.009) and triple negative phenotypes (P ≤ 0.041). pMVD and GMP did also associate with high-grade tumors (P ≤ 0.048). To conclude, high baseline MVD significantly predicted response to bevacizumab treatment. In contrast, pMVD, GMP, and the angiogenesis signature score, did not predict response, but associated with aggressive tumor features, including basal-like and triple-negative phenotypes.
Collapse
Affiliation(s)
- Kristi Krüger
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, Section for Pathology, Haukeland University Hospital, University of Bergen, Bergen, Norway
| | - Laxmi Silwal-Pandit
- Department of Cancer Genetics, Institute for Cancer Research, Division of Cancer Medicine, Surgery and Transplantation, Oslo University Hospital Radiumhospitalet, Oslo, Norway
| | - Elisabeth Wik
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, Section for Pathology, Haukeland University Hospital, University of Bergen, Bergen, Norway.,Department of Pathology, Haukeland University Hospital, Bergen, Norway
| | - Oddbjørn Straume
- Department of Oncology, Haukeland University Hospital, Bergen, Norway.,Centre for Cancer Biomarkers CCBIO, Department of Clinical Science, Section for Oncology, University of Bergen, Bergen, Norway
| | - Ingunn M Stefansson
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, Section for Pathology, Haukeland University Hospital, University of Bergen, Bergen, Norway.,Department of Pathology, Haukeland University Hospital, Bergen, Norway
| | - Elin Borgen
- Department of Pathology, Oslo University Hospital, Oslo, Norway
| | - Øystein Garred
- Department of Pathology, Oslo University Hospital, Oslo, Norway
| | - Bjørn Naume
- Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.,Institute for Clinical Medicine, University of Oslo, Oslo, Norway
| | - Olav Engebraaten
- Department of Oncology, Division of Cancer Medicine, Oslo University Hospital, Oslo, Norway.,Institute for Clinical Medicine, University of Oslo, Oslo, Norway
| | - Lars A Akslen
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, Section for Pathology, Haukeland University Hospital, University of Bergen, Bergen, Norway. .,Department of Pathology, Haukeland University Hospital, Bergen, Norway.
| |
Collapse
|
12
|
Exarchos V, Meyborg H, Krüger K, Giampietro C, Moimas S, Chala N, Cesarovic N, Emmert MY, Falk V, Ferrari A, Shafti MTN. The Rejuvenative Impact of Anisotropic Topographies on Senescent Endothelial Cells. Thorac Cardiovasc Surg 2021. [DOI: 10.1055/s-0041-1725649] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
13
|
Kristensen VM, Helgstrand T, Andersen JB, Krüger K, Jakobsen H. Prostatic cystadenoma. A case-report illustrating diagnosis and surgical management of an unusual condition. Scand J Urol 2020; 55:83-85. [PMID: 33356753 DOI: 10.1080/21681805.2020.1864465] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
Affiliation(s)
- Vibeke M Kristensen
- Department of Urology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
| | - Thomas Helgstrand
- Department of Urology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
| | - Janne Bayer Andersen
- Department of Urology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
| | - Kristi Krüger
- Department of Urology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
| | - Henrik Jakobsen
- Department of Urology, Herlev Hospital, University of Copenhagen, Copenhagen, Denmark
| |
Collapse
|
14
|
Abstract
BACKGROUND Welders demonstrate a high prevalence of musculoskeletal disorders (MSDs), as indicated by high rates of illness-related absenteeism. Leisure time physical activity (LTPA) could be a preventive strategy. However, little is known about LTPA prevalence and its association with MSDs among welders. AIMS The aim of this study was to analyse the prevalence of MSD and LTPA levels among welders and to identify risk factors for the main disorder of low back pain (LBP). METHODS The following data were collected from 145 welders from 34 companies in the German steel industry: individual factors (demographics, health behaviour), job-related factors (welding process, welding hours per day, employment years, shift work, ergonomic tools) and MSD (Nordic questionnaire). LTPA (International Physical Activity Questionnaire) was calculated to determine the metabolic equivalent of task (MET) per week as an objective measure of energy expenditure. Prevalence and multivariate regression analysis were calculated to determine odds ratios (ORs). RESULTS The 12-month prevalence of LBP was 71%, for neck pain 61% and for shoulder pain 55%. Forty-two per cent of the participants accumulated <600 MET/week. The multivariate regression model revealed LTPA <600 MET/week (OR 3.4, 95% CI 1.05-10.85) and neck pain in the previous 12 months (OR 5.2, 95% CI 2.02-13.56) to be significantly associated with LBP. CONCLUSIONS The results show a high prevalence of MSDs and thus a strong requirement for intervention. Therefore, LTPA should be prioritized and employers should encourage access to regular activity.
Collapse
Affiliation(s)
- C Weyh
- Department of Exercise Physiology and Sports Therapy, Justus-Liebig-University, Kugelberg, Giessen, Germany
| | - C Pilat
- Department of Exercise Physiology and Sports Therapy, Justus-Liebig-University, Kugelberg, Giessen, Germany
| | - K Krüger
- Department of Exercise Physiology and Sports Therapy, Justus-Liebig-University, Kugelberg, Giessen, Germany
| |
Collapse
|
15
|
Tayebi S, Krüger K, Safakar M, Bahrami P, Tahmasb G, Nenasheva A. EFFECTS OF ZIZIPHUS JUJUBE SUPPLEMENTATION ON PRO- AND ANTI-APOPTOTIC PROTEIN EXPRESSION IN NEUTROPHILS AFTER RESISTANCE EXERCISE. hsm 2020. [DOI: 10.14529/hsm200301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Abstract
Introduction. It is suggested that jujube might have beneficial effects on exercise-induced immune perturbations, specifically on neutrophils apoptosis regulation, but its cellular mechanism is unclear. Aim. The aim of this study was to investigate the acute effect of Ziziphus jujuba administration on pro- and anti-apoptotic protein levels in human neutrophils in response to a session of circuit resistance exercise (Ex). Material and Methods. Participants completed an Ex (75 % 1RM, 9 exercises, 3 sets). While one group received a placebo, the other group (Zj) was supplemented daily with jujube (0.5 gr/kg body weight suspended in 2.5cc distilled water) one hour before Ex. Results. Ex increased the neutrophil level of [Ca2+]i, calpain-1 and caspase-3 (p < 0.05) while a reduction of calpastatin and XIAP were observed (p < 0.05). Zj either suppressed the [Ca2+]i or reversed the calpastatin, calpain-1, XIAP, and caspase-3 responses (p < 0.01). Conclusions. The data indicate that a single session of intensive Ex induced apoptotic signaling in human neutrophils with the involvement of [Ca2+]i-calpastatin-calpain axis upstream caspase-3. Acute administration of jujube solution before exercise attenuated these effects probably by providing energy sources for neutrophils or by functioning as antioxidants.
Collapse
|
16
|
Krüger K. Interstitielle Lungenerkrankung (ILD) – wann und wie behandeln? Z Rheumatol 2020; 79:780-781. [DOI: 10.1007/s00393-020-00829-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022]
|
17
|
Krüger K. Komorbiditäten-Assessment durch die Fachassistentin – die ERIKO-Studie. Z Rheumatol 2020; 79:55-56. [DOI: 10.1007/s00393-020-00865-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
18
|
Affiliation(s)
- A Krause
- Abteilung Rheumatologie, Klinische Immunologie und Osteologie, Immanuel Krankenhaus Berlin, Königstraße 63, 14109, Berlin, Deutschland.
| | - K Krüger
- Rheumatologisches Praxiszentrum, München, Deutschland
| | - J Braun
- Rheumazentrum Ruhrgebiet und Ruhr-Universität Bochum, Herne, Deutschland
| | - G Gauler
- Rheumapraxis an der Hase, Osnabrück, Deutschland
| | - K Hoeper
- Klinik für Immunologie und Rheumatologie, Medizinische Hochschule Hannover, Hannover, Deutschland
| | - F Schuch
- Internistische Praxisgemeinschaft Rheumatologie - Nephrologie, Erlangen, Deutschland
| | - A J Voormann
- Deutsche Gesellschaft für Rheumatologie, Berlin, Deutschland
| |
Collapse
|
19
|
Abstract
Modern rheumatology enables better and earlier diagnosis and therapy of inflammatory rheumatic system diseases. At the same time, the requirements for the care of rheumatologic patients have risen considerably for non-medical assistant professions and specialists for nursing professions. Since 2006 there has been established an education curriculum "Rheumatological Specialist Assistant DGRh-BDRh" (RFA) with the training to become a "Rheumatological Specialist Assistant (DGRh-BDRh)". In Europe and in parallel in Germany, assistant professions are increasingly involved in the early detection and care of patients with rheumatic diseases and entrusted with tasks.In this work, the overarching principles for delegation of medical tasks to RFA and recommendations for the delegation are published by the Commission for Delegation of the German Society for Rheumatology (DGRh). These recommendations are based on the requirements of the German Medical Association and have been legally evaluated. With the extension of the training of the RFA board certification is aimed for "MFA for Rheumatology". These recommendations enable more transparency and security for delegating doctors and the delegated RFA's.
Collapse
Affiliation(s)
- A Krause
- Klinik für Innere Medizin, Abteilung Rheumatologie, Klinische Immunologie und Osteologie, Immanuel Krankenhaus Berlin, Königstr. 63, 14109, Berlin, Deutschland.
| | - F Schuch
- Rheumatologische Schwerpunktpraxis Erlangen, Erlangen, Deutschland
| | - J Braun
- Rheumazentrum Ruhrgebiet, Lehrstuhl für Rheumatologie, Ruhr Universität Bochum, Bochum, Deutschland
| | - G Gauler
- Rheumapraxis, Else Brandström Str., Osnabrück, Deutschland
| | - K Hoeper
- Klinik für Immunologie und Rheumatologie, Medizinische Hochschule Hannover, Hannover, Deutschland
| | - K Krüger
- Praxiszentrum St. Bonifatius, München, Deutschland
| | - M Wallhäuser
- PPP Rechtsanwälte, Bergisch Gladbach, Deutschland
| | - A J Voormann
- Dt. Gesellschaft für Rheumatologie, Berlin, Deutschland
| |
Collapse
|
20
|
Fiehn C, Ness T, Weseloh C, Specker C, Hadjiski D, Detert J, Krüger K. [Safety management of the treatment with antimalarial drugs in rheumatology. Interdisciplinary recommendations based on a systematic literature search]. Z Rheumatol 2020; 79:186-194. [PMID: 32095892 DOI: 10.1007/s00393-020-00751-0] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
Abstract
BACKGROUND Antimalarial medication (AM) plays an important role in the treatment of rheumatic diseases. OBJECTIVE Updated evidence-based recommendations on the safety management of rheumatological treatment with AM are presented. METHODS A systematic literature search in the databases Medline (PubMed) and Cochrane identified 1160 studies on the safety of treatment with AM in rheumatology. In addition, a manual search was carried out and 67 publications considered to be particularly relevant by the authors were analyzed in more detail. These publications served as a basis for consensus-based recommendations. RESULTS Treatment with AM in rheumatology should be carried out with hydroxychloroquine (HCQ) with a dosage not exceeding 5 mg/kg body weight/day. Patients should undergo a basic ophthalmological examination within the first 6 months of AM treatment. Pre-existing maculopathy, renal insufficiency (glomerular filtration rate, GFR <60 ml/min), tamoxifen comedication, a daily dose of >5 mg/kg HCQ or treatment with chloroquine (CQ) show an increased risk for AM-induced retinopathy. These patients should undergo an annual ophthalmological check from the beginning of the treatment, whereas patients with no risk factors are recommended to start this only after 5 years of taking the medication. The ophthalmological examination should comprise at least both an appropriate subjective and an objective method and these are usually an automated visual field test and optical coherence tomography (OCT). A visual field test revealing a parafoveal sensitivity loss and an OCT showing a parafoveal circumscribed loss of the photoreceptor layer or focal interruptions of the structural line of the outer segment are signs of a possible AM retinopathy. Determination of creatine kinase (CK) and lactate dehydrogenase (LDH) in blood is appropriate to screen for cardiomyopathy and myopathy and should be checked before starting the treatment and then ca. every 3 months. The use of cardiac biomarkers, such as brain natriuretic peptide (BNP) or troponin in serum, electrocardiograph (ECG) or cardiac imaging should be considered depending on the situation. An intake of HCQ is safe during pregnancy and breastfeeding according to the current state of knowledge and is protective for mother and child in patients with systemic lupus erythematosus. CONCLUSION The updated recommendations on AM treatment in rheumatology in particular include a more rigorous measuring of doses, risk stratification in monitoring and defined ophthalmological examination methods to detect a possible retinopathy.
Collapse
Affiliation(s)
- C Fiehn
- Rheumatologie Baden-Baden GbR, Tätigkeitsschwerpunkt Klinische Immunologie und Belegarzteinheit der ViDia-Kliniken Karlsruhe, Medical Center Baden-Baden, Beethovenstr. 2, 76530, Baden-Baden, Deutschland.
| | - T Ness
- Klinik für Augenheilkunde, Universitätsklinik Freiburg, Freiburg, Deutschland
| | - C Weseloh
- Deutsche Gesellschaft für Rheumatologie, Berlin, Deutschland
| | - C Specker
- Klinik für Rheumatologie und Klinische Immunologie, Kliniken Essen-Mitte, Essen, Deutschland
| | - D Hadjiski
- Rheumatologie Baden-Baden GbR, Tätigkeitsschwerpunkt Klinische Immunologie und Belegarzteinheit der ViDia-Kliniken Karlsruhe, Medical Center Baden-Baden, Beethovenstr. 2, 76530, Baden-Baden, Deutschland
| | - J Detert
- Rheumatologisch-immunologische Arztpraxis, Templin, Deutschland
| | - K Krüger
- Praxiszentrum St. Bonifatius, München, Deutschland
| |
Collapse
|
21
|
Leipe J, Hoyer BF, Iking-Konert C, Schulze-Koops H, Specker C, Krüger K. [SARS-CoV-2 & rheumatic disease : Consequences of the SARS-CoV-2 pandemic for patients with inflammatory rheumatic diseases. A comparison of the recommendations for action of rheumatological societies and risk assessment of different antirheumatic treatments]. Z Rheumatol 2020; 79:686-691. [PMID: 32845393 PMCID: PMC7448266 DOI: 10.1007/s00393-020-00878-0] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 08/20/2020] [Indexed: 02/06/2023]
Abstract
The recommendations of the German Society of Rheumatology (DGRh) update, which update and expand the guidance on the management of patients with inflammatory rheumatic diseases in view of SARS-CoV‑2 created at the beginning of the COVID-19 pandemic, correspond in many points with the recommendations for action of the American (ACR) and European (EULAR) societies, but also differ in some points. Therefore, this article discusses the core recommendations of the DGRh update on the prevention of SARS-CoV-2/COVID-19, the risk assessment for inflammatory rheumatic diseases and the use of antirheumatic treatments in the context and in comparison to the ACR and EULAR recommendations, and provides an overview of the risk assessment of individual antirheumatic drugs.
Collapse
Affiliation(s)
- J Leipe
- Sektion Rheumatologie, Medizinische Klinik V, Universitätsklinikum Mannheim, Theodor-Kutzer-Ufer 1-3, 68167, Mannheim, Deutschland. .,Sektion Rheumatologie und Klinische Immunologie, Medizinische Klinik und Poliklinik IV, Ludwig-Maximilians-Universität München, München, Deutschland.
| | - B F Hoyer
- Abteilung für Rheumatologie, 1. Medizinische Klinik, Universitätskrankenhaus Schleswig-Holstein Campus Kiel, Kiel, Deutschland
| | - C Iking-Konert
- III. Medizinische Klinik und Poliklinik Sektion Rheumatologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland
| | - H Schulze-Koops
- Sektion Rheumatologie und Klinische Immunologie, Medizinische Klinik und Poliklinik IV, Ludwig-Maximilians-Universität München, München, Deutschland
| | - C Specker
- Klinik für Rheumatologie und Klinische Immunologie, Kliniken Essen-Mitte, Essen, Deutschland
| | - K Krüger
- Rheumatologisches Praxiszentrum München, München, Deutschland
| |
Collapse
|
22
|
Mooren FC, Maleki BH, Pilat C, Ringseis R, Eder K, Teschler M, Krüger K. Effects of Escherichia coli strain Nissle 1917 on exercise-induced disruption of gastrointestinal integrity. Eur J Appl Physiol 2020; 120:1591-1599. [PMID: 32399590 PMCID: PMC7295722 DOI: 10.1007/s00421-020-04382-w] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2019] [Accepted: 04/23/2020] [Indexed: 12/18/2022]
Abstract
PURPOSE The aim of the current study was to investigate the effects of the probiotic Escherichia coli strain Nissle 1917 (EcN) on the exercise-induced disruption of gastrointestinal (GI) integrity and the associated release of damage and inflammatory markers. METHODS After a pre-performance test, 19 untrained subjects (aged 18-35 years) passed two identical exhaustive treadmill exercise tests in an intensity corresponding to 60-80% VO2max in a test-retest design. The exercise tests were separated by a time period of 4 weeks. During this period, all subjects ingested 5 ml of an EcN suspension daily. Serum samples were taken before, immediately following and 3 h after both exercise tests. They were analyzed for indicators of GI integrity (zonulin; claudin-3; LPS), various damage and redox markers (I-FABP, GOT; GPT; TBARS) and inflammatory parameters (hsCRP; leucocytes). GI complaints were evaluated by a questionnaire. RESULTS The intake of EcN resulted in a significantly lower increase in I-FABP and TBARS after exercise (p < 0.05). In contrast, no effect of EcN supplementation was found for hsCRP and leucocyte numbers. Similarly, no differences were found for levels of zonulin and claudin-3. Exercise-associated GI complaints were not affected by the probiotic supplement. CONCLUSION The probiotic EcN reduced the exercise-associated increase in oxidative stress. This antioxidative mechanism probably leads to a reduction of GI epithelial damage after exhaustive exercise. The lack of EcN effects on other markers of GI permeability and systemic inflammation is most likely due to an inadequate exercise load, with rather small and insignificant exercise effects on these parameters.
Collapse
Affiliation(s)
- F C Mooren
- Faculty of Health, School of Medicine, Witten/Herdecke University, Witten, Germany.
| | - B H Maleki
- Department of Exercise Physiology and Sports Therapy, Institute of Sports Sciences, Justus-Liebig-University, Giessen, Germany
| | - C Pilat
- Department of Exercise Physiology and Sports Therapy, Institute of Sports Sciences, Justus-Liebig-University, Giessen, Germany
| | - R Ringseis
- Institute of Animal Nutrition and Nutrition Physiology, Justus-Liebig-University, Giessen, Germany
| | - K Eder
- Institute of Animal Nutrition and Nutrition Physiology, Justus-Liebig-University, Giessen, Germany
| | - M Teschler
- Faculty of Health, School of Medicine, Witten/Herdecke University, Witten, Germany
| | - K Krüger
- Department of Exercise Physiology and Sports Therapy, Institute of Sports Sciences, Justus-Liebig-University, Giessen, Germany
| |
Collapse
|
23
|
Schulze-Koops H, Holle J, Moosig F, Specker C, Aries P, Burmester G, Fiehn C, Hoyer B, Krause A, Leipe J, Lorenz HM, Schneider M, Sewerin P, Voormann A, Wager U, Krüger K, Iking-Konert C. [Current guidance of the German Society of Rheumatology for the care of patients with rheumatic diseases during the SARS-CoV-2/Covid 19 pandemic]. Z Rheumatol 2020; 79:385-388. [PMID: 32342184 PMCID: PMC7184809 DOI: 10.1007/s00393-020-00799-y] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
In der aktuellen SARS-CoV-2 Pandemie bestehen viele Fragen mit Blick auf die sichere Behandlung von Patienten mit entzündlich-rheumatischen Erkrankungen. Auf viele dieser Fragen gibt es zur Zeit noch keine evidenzbasierte Antwort und das macht die Betreuung der Patienten nicht leicht. Die Deutsche Gesellschaft für Rheumatologie e. V. (DGRh) will mit diesen ersten Empfehlungen Hilfestellung für spezielle Belange in der Betreuung von Rheumapatienten angesichts der aktuellen Bedrohung durch SARS-CoV-2 geben. Um den dynamischen weltweiten Erkenntnisgewinn für unsere Patienten zu nutzen, werden die Empfehlungen regelmäßig aktualisiert. Die aktualisierten Versionen der Empfehlungen werden auf der Homepage der DGRh hinterlegt.
Collapse
Affiliation(s)
- H Schulze-Koops
- Deutsche Gesellschaft für Rheumatologie e. V., Berlin, Deutschland. .,Sektion Rheumatologie und Klinische Immunologie, Medizinische Klinik IV, Ludwig-Maximilians-Universität München, Pettenkoferstraße 8a, München, Deutschland.
| | - J Holle
- Rheumazentrum Schleswig-Holstein Mitte, Neumünster, Deutschland
| | - F Moosig
- Rheumazentrum Schleswig-Holstein Mitte, Neumünster, Deutschland
| | - C Specker
- Deutsche Gesellschaft für Rheumatologie e. V., Berlin, Deutschland.,Klinik für Rheumatologie und Klinische Immunologie, Kliniken Essen-Mitte, Essen, Deutschland
| | - P Aries
- Rheumatologie im Struenseehaus, Hamburg, Deutschland
| | - G Burmester
- Klinik für Rheumatologie und Klinische Immunologie, Charité - Universitäts Medizin Berlin, Freie Universität und Humboldt Universität Berlin, Berlin, Deutschland
| | - C Fiehn
- Medical Center Baden-Baden und ViDia-Kliniken Karlsruhe, Praxis für Rheumatologie und Klinische Immunologie, Baden-Baden, Deutschland
| | - B Hoyer
- Abteilung für Rheumatologie, 1. Medizinische Klinik, Universitätskrankenhaus Schleswig-Holstein Campus Kiel, Kiel, Deutschland
| | - A Krause
- Deutsche Gesellschaft für Rheumatologie e. V., Berlin, Deutschland.,Abteilung für Rheumatologie, Osteologie und Klinische Immunologie, Immanuel Krankenhaus Berlin, Berlin, Deutschland
| | - J Leipe
- Abteilung für Rheumatologie, Medizinische Klinik V, Universitätskrankenhaus Mannheim, Mannheim, Deutschland
| | - H-M Lorenz
- Deutsche Gesellschaft für Rheumatologie e. V., Berlin, Deutschland.,Abteilung für Rheumatologie, Medizinische Klinik V, Universitätsklinikum Heidelberg, Heidelberg, Deutschland
| | - M Schneider
- Poliklinik, Funktionsbereich und Hiller Forschungszentrum für Rheumatologie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Deutschland
| | - P Sewerin
- Poliklinik, Funktionsbereich und Hiller Forschungszentrum für Rheumatologie, Universitätsklinikum Düsseldorf, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Deutschland
| | - A Voormann
- Deutsche Gesellschaft für Rheumatologie e. V., Berlin, Deutschland
| | - U Wager
- Deutsche Gesellschaft für Rheumatologie e. V., Berlin, Deutschland.,Abteilung für Rheumatologie, Klinik und Poliklinik für Endokrinologie, Nephrologie, Rheumatologie, Universitätsklinikum Leipzig, Leipzig, Deutschland
| | - K Krüger
- Rheumatologisches Praxiszentrum, Kommission Pharmakotherapie der DGRh e. V., St. Bonifatius-Straße 5, 81541, München, Deutschland.
| | - C Iking-Konert
- III. Medizinische Klinik und Poliklinik Sektion Rheumatologie, Universitätsklinikum Hamburg-Eppendorf, Hamburg, Deutschland
| | | |
Collapse
|
24
|
Wackerhage H, Everett R, Krüger K, Murgia M, Simon P, Gehlert S, Neuberger E, Baumert P, Schönfelder M. Sport, exercise and COVID-19, the disease caused by the SARS-CoV-2 coronavirus. Dtsch Z Sportmed 2020. [DOI: 10.5960/dzsm.2020.441] [Citation(s) in RCA: 30] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
25
|
Leißner T, Diener A, Löwer E, Ditscherlein R, Krüger K, Kwade A, Peuker U. 3D ex-situ and in-situ X-ray CT process studies in particle technology – A perspective. ADV POWDER TECHNOL 2020. [DOI: 10.1016/j.apt.2019.09.038] [Citation(s) in RCA: 17] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
26
|
Kula A, Liersch S, Krüger K, Walter U, Hagen A. Obesity prevention - is school an effective place? A systematic review. Eur J Public Health 2019. [DOI: 10.1093/eurpub/ckz187.049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Background
Juvenile and childhood obesity or overweight are associated with various secondary diseases and physical limitations, as well as with the effects of discrimination and social exclusion. The early prevention of obesity remains a key area of action worldwide. Schools are considered as a classical setting. The analysis focuses on the effectiveness of interventions, the identification of effective components and conditions as well as barriers. The aim is to provide a differentiated presentation of the current study situation.
Methods
The systematic literature search in eleven databases included studies in English and German published in 1990 to 2015. A control group and posttest data were obligatory. Evaluated outcome measures must map effects on the prevalence of obesity (e.g., BMI, body fat percentage, waist-to-hip ratio). Included full texts were evaluated with the instrument ROBINS-I. Due to the heterogeneity of studies (especially in terms of design, intervention and outcomes) results were analysed qualitatively.
Results
48 primary studies were included of which most studies report data on changes in mean BMI over time, and show predominantly (small) effects in favour of the intervention. Almost all identified interventions include behavioral measures, most of them combine the fields of nutrition and physical activity, with behavioral prevention being overrepresented in particular in activities addressing nutrition.
Conclusions
The results allow the conclusion, that school-based measures to prevent obesity are effective in terms of anthropometric outcome measures, but to a limited extent. There is clear evidence that the effects achieved tend to be maintained beyond the intervention. There are also clear indications for the cost-effectiveness of school-based obesity prevention. The studies from this field of research have clearly gained in quality over the years and are now flanked by health economic analyses.
Funded by DIMDI
Key messages
School-based measures to prevent obesity are effective in terms of anthropometric outcome measures, but to a limited extent. In order to fully realize its potential, school-based measures to prevent obesity should be accompanied by interventions at other levels, like the health-promoting design of living environments.
Collapse
Affiliation(s)
- A Kula
- MHH, Institute for Epidemiology, Social Medicine and Health System Research, Hannover, Germany
| | - S Liersch
- MHH, Institute for Epidemiology, Social Medicine and Health System Research, Hannover, Germany
| | - K Krüger
- MHH, Institute for Epidemiology, Social Medicine and Health System Research, Hannover, Germany
| | - U Walter
- MHH, Institute for Epidemiology, Social Medicine and Health System Research, Hannover, Germany
| | - A Hagen
- MHH, Institute for Epidemiology, Social Medicine and Health System Research, Hannover, Germany
| |
Collapse
|
27
|
|
28
|
Palmowski J, Boßlau TK, Ryl L, Krüger K, Reichel T. Managing immune health in sports – a practical guide for athletes and coaches. Dtsch Z Sportmed 2019. [DOI: 10.5960/dzsm.2019.389] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
29
|
Pérez-Rodríguez J, Krüger K, Pérez-Hedo M, Ruíz-Rivero O, Urbaneja A, Tena A. Classical biological control of the African citrus psyllid Trioza erytreae, a major threat to the European citrus industry. Sci Rep 2019; 9:9440. [PMID: 31263114 PMCID: PMC6603031 DOI: 10.1038/s41598-019-45294-w] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2019] [Accepted: 06/04/2019] [Indexed: 11/14/2022] Open
Abstract
Citrus greening or huanglongbing (HLB) is the main threat to the European citrus industry since one of its vectors, the African citrus psyllid, Trioza erytreae, has recently become established in mainland Europe. In this context, classical biological control programmes should be implemented to reduce the spread of the psyllid. The aims of this study were to: i) disentangle the parasitoid complex of T. erytreae combining morphological and molecular characterization; and ii) to study the biology of its main parasitoids in its area of origin in South Africa for their future importation into Europe. The main citrus producing areas of South Africa were surveyed during 2017. In contrast to previous studies, the parasitoid complex of T. erytreae included three species of primary parasitoids: Tamarixia dryi, Psyllaephagus pulvinatus and another parasitoid of the genus Tamarixia. Molecular analysis showed that it is a new species closely related to T. dryi. Tamarixia dryi was the most abundant parasitoid but its relative abundance varied among sampling sites. The sex ratio (males/females) of T. dryi and Tamarixia sp. decreased with T. erytreae size and became female biased when psyllid nymphs were larger than 0.6 and 1.2 mm2, respectively. These parasitoids were attacked by three species of hyperparasitoids, Aphidencyrtus cassatus, Marietta javensis and a species of the genus Aphanogmus. Aphidencyrtus cassatus, the most abundant hyperparasitoid, tended to emerge from large nymphs, and adult females lived as long as those of T. dryi. The implications of these results are discussed within the framework of the introduction of T. dryi into Europe.
Collapse
Affiliation(s)
- J Pérez-Rodríguez
- Centro de Protección Vegetal y Biotecnología, Instituto Valenciano de Investigaciones Agrarias (IVIA), Carretera Moncada-Náquera km 4.5, 46113, Moncada, Valencia, Spain.,Laboratori d'Investigació d'Entomologia, Departament de Zoologia, Facultat de Ciències Biològiques, Carrer Doctor Moliner s/n, 46100, Burjassot, València, Spain
| | - K Krüger
- Department of Zoology and Entomology, University of Pretoria, Private Bag X20, Pretoria, 0028, South Africa
| | - M Pérez-Hedo
- Centro de Protección Vegetal y Biotecnología, Instituto Valenciano de Investigaciones Agrarias (IVIA), Carretera Moncada-Náquera km 4.5, 46113, Moncada, Valencia, Spain
| | - O Ruíz-Rivero
- Centro de Protección Vegetal y Biotecnología, Instituto Valenciano de Investigaciones Agrarias (IVIA), Carretera Moncada-Náquera km 4.5, 46113, Moncada, Valencia, Spain
| | - A Urbaneja
- Centro de Protección Vegetal y Biotecnología, Instituto Valenciano de Investigaciones Agrarias (IVIA), Carretera Moncada-Náquera km 4.5, 46113, Moncada, Valencia, Spain
| | - A Tena
- Centro de Protección Vegetal y Biotecnología, Instituto Valenciano de Investigaciones Agrarias (IVIA), Carretera Moncada-Náquera km 4.5, 46113, Moncada, Valencia, Spain.
| |
Collapse
|
30
|
Abstract
Due to therapeutic advances, rheumatoid arthritis (RA) today has developed into a satisfactorily treatable disease in most cases, with remission being the target of treatment. Early diagnosis with immediate treatment initiation following treat-to-target strategy is the key to a favorable long-term outcome. A guideline-directed treatment algorithm determines the use of conventional synthetic disease-modifying anti-rheumatic drugs (DMARD; e.g., methotrexate), biological DMARD, and targeted oral DMARD (Janus kinase inhibitors). Comorbidities-in particular cardiovascular and interstitial lung disease-affect 80% of RA patients and represent the leading causes for mortality. The choice of drug treatment is influenced by the presence of comorbidities.
Collapse
Affiliation(s)
- K Krüger
- Rheumatologisches Praxiszentrum München, St.-Bonifatius-Str. 5, 81541, München, Deutschland.
| |
Collapse
|
31
|
|
32
|
Krüger K. [Biologics and further new drugs for rheumatic diseases since 2000]. Orthopade 2018; 47:906-911. [PMID: 30280235 DOI: 10.1007/s00132-018-3650-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
BACKGROUND Rheumatoid arthritis (RA), psoriatic arthritis and axial spondyloarthritis are severe diseases, which without adequate treatment lead to extremely reduced mobility, functional status and quality of life. OBJECTIVE The effects of biologics and further new antirheumatic drugs on the burden of disease. METHODS Evaluation of study results and register data dealing with the efficacy and safety of these drugs. RESULTS Biologics have been proven to dramatically improve the outcome of all three diseases and contributed to the fact that remission is a realistic target today. In addition, the cardiovascular risk and mortality in RA have been reduced and structural damage is considerably blocked by biologics. Recently Janus kinase (JAK) inhibitors contributed to the treatment possibilities in the same way. Biologics as well as JAK inhibitors offer an excellent safety profile and tolerability with infections being the most important risk. CONCLUSION With the availability of biologics and additional new drugs all three diseases have lost the status of difficult to treat diseases. Their usage according to the guidelines ensures that the burden of disease can been minimalized in most cases. The benefit-risk profile of these drugs has been shown to be excellent.
Collapse
Affiliation(s)
- K Krüger
- Rheumatologisches Praxiszentrum, St. Bonifatius Str. 5, 81541, München, Deutschland.
| |
Collapse
|
33
|
Kula A, Liersch S, Krüger K, Walter U, Hagen A. Einzelbeitrag: Adipositasprävention – ist Schule ein wirksamer Ort? – ein systematisches Review. Das Gesundheitswesen 2018. [DOI: 10.1055/s-0038-1667746] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- A Kula
- Medizinische Hochschule Hannover, Institut für Epidemiologie, Sozialmedizin und Gesundheitssystemforschung, Hannover, Deutschland
| | - S Liersch
- Medizinische Hochschule Hannover, Institut für Epidemiologie, Sozialmedizin und Gesundheitssystemforschung, Hannover, Deutschland
| | - K Krüger
- Medizinische Hochschule Hannover, Institut für Epidemiologie, Sozialmedizin und Gesundheitssystemforschung, Hannover, Deutschland
| | - U Walter
- Medizinische Hochschule Hannover, Institut für Epidemiologie, Sozialmedizin und Gesundheitssystemforschung, Hannover, Deutschland
| | - A Hagen
- Medizinische Hochschule Hannover, Institut für Epidemiologie, Sozialmedizin und Gesundheitssystemforschung, Hannover, Deutschland
| |
Collapse
|
34
|
Kleinert S, La Rosée P, Krüger K. [Rheumatoid symptoms in patients with hematologic neoplasms]. Z Rheumatol 2018; 76:38-45. [PMID: 29330756 DOI: 10.1007/s00393-017-0338-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Paraneoplastic syndromes in lymphatic or myeloid neoplasms can present with musculoskeletal symptoms, vasculitis-like or febrile symptoms. Hematologic diseases are also associated with rheumatic diseases whereas inflammatory rheumatic diseases are often associated with an increased risk for lymphoproliferative disease. Atypical disease characteristics, lack of disease-specific antibodies or therapeutic response are red flags for diagnosing paraneoplastic or coexistent malignant diseases. New onset of systemic symptoms, worsening of general condition, night sweats or weight loss need to be considered during follow-up and differential diagnostics. This article focuses on musculoskeletal, vasculitis-like and systemic signs of lymphatic or myeloid neoplasms either because of coexistency, tumor association or paraneoplastic disease.
Collapse
Affiliation(s)
- S Kleinert
- Rheumatologische Schwerpunktpraxis, Praxisgemeinschaft Rheumatologie - Nephrologie, Möhrendorfer Str. 1c, 91056, Erlangen, Deutschland.
| | - P La Rosée
- Klinik für Innere Medizin II, Onkologie, Hämatologie, Immunologie, Infektiologie und Palliativmedizin, Schwarzwald-Baar-Klinikum, Villingen-Schwenningen, Deutschland
| | - K Krüger
- Praxiszentrum St Bonifatius, München, Deutschland
| |
Collapse
|
35
|
|
36
|
Andreev V, Baghdasaryan A, Begzsuren K, Belousov A, Bertone V, Bolz A, Boudry V, Brandt G, Brisson V, Britzger D, Buniatyan A, Bylinkin A, Bystritskaya L, Campbell AJ, Cantun Avila KB, Cerny K, Chekelian V, Contreras JG, Cvach J, Currie J, Dainton JB, Daum K, Diaconu C, Dobre M, Dodonov V, Eckerlin G, Egli S, Elsen E, Favart L, Fedotov A, Feltesse J, Fleischer M, Fomenko A, Gabathuler E, Gayler J, Gehrmann T, Ghazaryan S, Goerlich L, Gogitidze N, Gouzevitch M, Grab C, Grebenyuk A, Greenshaw T, Grindhammer G, Gwenlan C, Haidt D, Henderson RCW, Hladkỳ J, Hoffmann D, Horisberger R, Hreus T, Huber F, Huss A, Jacquet M, Janssen X, Jung AW, Jung H, Kapichine M, Katzy J, Kiesling C, Klein M, Kleinwort C, Kogler R, Kostka P, Kretzschmar J, Krücker D, Krüger K, Landon MPJ, Lange W, Laycock P, Lebedev A, Levonian S, Lipka K, List B, List J, Lobodzinski B, Malinovski E, Martyn HU, Maxfield SJ, Mehta A, Meyer AB, Meyer H, Meyer J, Mikocki S, Morozov A, Müller K, Naumann T, Newman PR, Niebuhr C, Niehues J, Nowak G, Olsson JE, Ozerov D, Pascaud C, Patel GD, Perez E, Petrukhin A, Picuric I, Pirumov H, Pitzl D, Plačakytė R, Polifka R, Rabbertz K, Radescu V, Raicevic N, Ravdandorj T, Reimer P, Rizvi E, Robmann P, Roosen R, Rostovtsev A, Rotaru M, Šálek D, Sankey DPC, Sauter M, Sauvan E, Schmitt S, Schoeffel L, Schöning A, Sefkow F, Shushkevich S, Soloviev Y, Sopicki P, South D, Spaskov V, Specka A, Steder M, Stella B, Straumann U, Sutton MR, Sykora T, Thompson PD, Traynor D, Truöl P, Tsakov I, Tseepeldorj B, Valkárová A, Vallée C, Van Mechelen P, Vazdik Y, Wegener D, Wünsch E, Žáček J, Zhang Z, Žlebčík R, Zohrabyan H, Zomer F. Determination of the strong coupling constant α s ( m Z ) in next-to-next-to-leading order QCD using H1 jet cross section measurements: H1 Collaboration. Eur Phys J C Part Fields 2017; 77:791. [PMID: 31997933 PMCID: PMC6956906 DOI: 10.1140/epjc/s10052-017-5314-7] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/22/2017] [Accepted: 10/12/2017] [Indexed: 06/08/2023]
Abstract
The strong coupling constant α s is determined from inclusive jet and dijet cross sections in neutral-current deep-inelastic ep scattering (DIS) measured at HERA by the H1 collaboration using next-to-next-to-leading order (NNLO) QCD predictions. The dependence of the NNLO predictions and of the resulting value ofα s ( m Z ) at the Z-boson mass m Z are studied as a function of the choice of the renormalisation and factorisation scales. Using inclusive jet and dijet data together, the strong coupling constant is determined to beα s ( m Z ) = 0.1157 ( 20 ) exp ( 29 ) th . Complementary,α s ( m Z ) is determined together with parton distribution functions of the proton (PDFs) from jet and inclusive DIS data measured by the H1 experiment. The valueα s ( m Z ) = 0.1142 ( 28 ) tot obtained is consistent with the determination from jet data alone. The impact of the jet data on the PDFs is studied. The running of the strong coupling is tested at different values of the renormalisation scale and the results are found to be in agreement with expectations.
Collapse
Affiliation(s)
- V. Andreev
- Lebedev Physical Institute, Moscow, Russia
| | | | - K. Begzsuren
- Institute of Physics and Technology of the Mongolian Academy of Sciences, Ulaanbaatar, Mongolia
| | | | - V. Bertone
- Department of Physics and Astronomy, Vrije University, De Boelelaan 1081, Amsterdam, The Netherlands
- National Institute for Subatomic Physics (NIKHEF), Science Park 105, Amsterdam, The Netherlands
| | - A. Bolz
- Physikalisches Institut, Universität Heidelberg, Heidelberg, Germany
| | - V. Boudry
- LLR, Ecole Polytechnique, CNRS/IN2P3, Palaiseau, France
| | - G. Brandt
- II. Physikalisches Institut, Universität Göttingen, Göttingen, Germany
| | - V. Brisson
- LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
| | - D. Britzger
- Physikalisches Institut, Universität Heidelberg, Heidelberg, Germany
| | - A. Buniatyan
- School of Physics and Astronomy, University of Birmingham, Birmingham, UK
| | - A. Bylinkin
- Moscow Institute of Physics and Technology, Dolgoprudny, Moscow Region Russian Federation
| | - L. Bystritskaya
- Institute for Theoretical and Experimental Physics, Moscow, Russia
| | | | | | - K. Cerny
- Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic
| | | | - J. G. Contreras
- Departamento de Fisica Aplicada, CINVESTAV, Mérida, Yucatán Mexico
| | - J. Cvach
- Institute of Physics, Academy of Sciences of the Czech Republic, Prague, Czech Republic
| | - J. Currie
- Institute for Particle Physics Phenomenology, Ogden Centre for Fundamental Physics, Durham University, South Road, Durham, UK
| | - J. B. Dainton
- Department of Physics, University of Liverpool, Liverpool, UK
| | - K. Daum
- Fachbereich C, Universität Wuppertal, Wuppertal, Germany
| | - C. Diaconu
- Aix Marseille Université, CNRS/IN2P3, CPPM UMR 7346, 13288 Marseille, France
| | - M. Dobre
- Horia Hulubei National Institute for R&D in Physics and Nuclear Engineering (IFIN-HH), Bucharest, Romania
| | | | | | - S. Egli
- Paul Scherrer Institute, Villigen, Switzerland
| | | | - L. Favart
- Inter-University Institute for High Energies ULB-VUB, Brussels and Universiteit Antwerpen, Antwerp, Belgium
| | - A. Fedotov
- Institute for Theoretical and Experimental Physics, Moscow, Russia
| | | | | | - A. Fomenko
- Lebedev Physical Institute, Moscow, Russia
| | - E. Gabathuler
- Department of Physics, University of Liverpool, Liverpool, UK
| | | | - T. Gehrmann
- Physik-Institut der Universität Zürich, Zurich, Switzerland
| | | | - L. Goerlich
- Institute of Nuclear Physics, Polish Academy of Sciences, 31342 Kraków, Poland
| | | | - M. Gouzevitch
- IPNL, Université Claude Bernard Lyon 1, CNRS/IN2P3, Villeurbanne, France
| | - C. Grab
- Institut für Teilchenphysik, ETH Zürich, Zurich, Switzerland
| | - A. Grebenyuk
- Inter-University Institute for High Energies ULB-VUB, Brussels and Universiteit Antwerpen, Antwerp, Belgium
| | - T. Greenshaw
- Department of Physics, University of Liverpool, Liverpool, UK
| | | | - C. Gwenlan
- Department of Physics, Oxford University, Oxford, UK
| | | | | | - J. Hladkỳ
- Institute of Physics, Academy of Sciences of the Czech Republic, Prague, Czech Republic
| | - D. Hoffmann
- Aix Marseille Université, CNRS/IN2P3, CPPM UMR 7346, 13288 Marseille, France
| | | | - T. Hreus
- Inter-University Institute for High Energies ULB-VUB, Brussels and Universiteit Antwerpen, Antwerp, Belgium
| | - F. Huber
- Physikalisches Institut, Universität Heidelberg, Heidelberg, Germany
| | - A. Huss
- Institut für Teilchenphysik, ETH Zürich, Zurich, Switzerland
| | - M. Jacquet
- LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
| | - X. Janssen
- Inter-University Institute for High Energies ULB-VUB, Brussels and Universiteit Antwerpen, Antwerp, Belgium
| | - A. W. Jung
- Department of Physics and Astronomy, Purdue University, 525 Northwestern Ave, West Lafayette, IN 47907 USA
| | | | - M. Kapichine
- Joint Institute for Nuclear Research, Dubna, Russia
| | | | - C. Kiesling
- Max-Planck-Institut für Physik, Munich, Germany
| | - M. Klein
- Department of Physics, University of Liverpool, Liverpool, UK
| | | | - R. Kogler
- Institut für Experimentalphysik, Universität Hamburg, Hamburg, Germany
| | - P. Kostka
- Department of Physics, University of Liverpool, Liverpool, UK
| | - J. Kretzschmar
- Department of Physics, University of Liverpool, Liverpool, UK
| | | | | | - M. P. J. Landon
- School of Physics and Astronomy, Queen Mary University of London, London, UK
| | | | - P. Laycock
- Department of Physics, University of Liverpool, Liverpool, UK
| | - A. Lebedev
- Lebedev Physical Institute, Moscow, Russia
| | | | | | | | | | | | | | - H.-U. Martyn
- I. Physikalisches Institut der RWTH, Aachen, Germany
| | - S. J. Maxfield
- Department of Physics, University of Liverpool, Liverpool, UK
| | - A. Mehta
- Department of Physics, University of Liverpool, Liverpool, UK
| | | | - H. Meyer
- Fachbereich C, Universität Wuppertal, Wuppertal, Germany
| | | | - S. Mikocki
- Institute of Nuclear Physics, Polish Academy of Sciences, 31342 Kraków, Poland
| | - A. Morozov
- Joint Institute for Nuclear Research, Dubna, Russia
| | - K. Müller
- Physik-Institut der Universität Zürich, Zurich, Switzerland
| | | | - P. R. Newman
- School of Physics and Astronomy, University of Birmingham, Birmingham, UK
| | | | - J. Niehues
- Physik-Institut der Universität Zürich, Zurich, Switzerland
| | - G. Nowak
- Institute of Nuclear Physics, Polish Academy of Sciences, 31342 Kraków, Poland
| | | | - D. Ozerov
- Paul Scherrer Institute, Villigen, Switzerland
| | - C. Pascaud
- LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
| | - G. D. Patel
- Department of Physics, University of Liverpool, Liverpool, UK
| | | | - A. Petrukhin
- IPNL, Université Claude Bernard Lyon 1, CNRS/IN2P3, Villeurbanne, France
| | - I. Picuric
- Faculty of Science, University of Montenegro, Podgorica, Montenegro
| | | | | | | | - R. Polifka
- Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic
- Department of Physics, University of Toronto, Toronto, ON M5S 1A7 Canada
| | - K. Rabbertz
- Karlsruher Institut für Technologie (KIT), Institut für Experimentelle Teilchenphysik (ETP), Wolfgang-Gaede-Str. 1, Karlsruhe, Germany
| | - V. Radescu
- Department of Physics, Oxford University, Oxford, UK
| | - N. Raicevic
- Faculty of Science, University of Montenegro, Podgorica, Montenegro
| | - T. Ravdandorj
- Institute of Physics and Technology of the Mongolian Academy of Sciences, Ulaanbaatar, Mongolia
| | - P. Reimer
- Institute of Physics, Academy of Sciences of the Czech Republic, Prague, Czech Republic
| | - E. Rizvi
- School of Physics and Astronomy, Queen Mary University of London, London, UK
| | - P. Robmann
- Physik-Institut der Universität Zürich, Zurich, Switzerland
| | - R. Roosen
- Inter-University Institute for High Energies ULB-VUB, Brussels and Universiteit Antwerpen, Antwerp, Belgium
| | - A. Rostovtsev
- Institute for Information Transmission Problems RAS, Moscow, Russia
| | - M. Rotaru
- Horia Hulubei National Institute for R&D in Physics and Nuclear Engineering (IFIN-HH), Bucharest, Romania
| | - D. Šálek
- Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic
| | - D. P. C. Sankey
- STFC, Rutherford Appleton Laboratory, Didcot, Oxfordshire UK
| | - M. Sauter
- Physikalisches Institut, Universität Heidelberg, Heidelberg, Germany
| | - E. Sauvan
- Aix Marseille Université, CNRS/IN2P3, CPPM UMR 7346, 13288 Marseille, France
- LAPP, Université de Savoie, CNRS/IN2P3, Annecy-le-Vieux, France
| | | | | | - A. Schöning
- Physikalisches Institut, Universität Heidelberg, Heidelberg, Germany
| | | | - S. Shushkevich
- Skobeltsyn Institute of Nuclear Physics, Lomonosov Moscow State University, Moscow, Russia
| | | | - P. Sopicki
- Institute of Nuclear Physics, Polish Academy of Sciences, 31342 Kraków, Poland
| | | | - V. Spaskov
- Joint Institute for Nuclear Research, Dubna, Russia
| | - A. Specka
- LLR, Ecole Polytechnique, CNRS/IN2P3, Palaiseau, France
| | | | - B. Stella
- Dipartimento di Fisica, Università di Roma Tre and INFN Roma 3, Rome, Italy
| | - U. Straumann
- Physik-Institut der Universität Zürich, Zurich, Switzerland
| | - M. R. Sutton
- Department of Physics and Astronomy, University of Sussex, Pevensey II, Brighton, UK
| | - T. Sykora
- Inter-University Institute for High Energies ULB-VUB, Brussels and Universiteit Antwerpen, Antwerp, Belgium
- Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic
| | - P. D. Thompson
- School of Physics and Astronomy, University of Birmingham, Birmingham, UK
| | - D. Traynor
- School of Physics and Astronomy, Queen Mary University of London, London, UK
| | - P. Truöl
- Physik-Institut der Universität Zürich, Zurich, Switzerland
| | - I. Tsakov
- Institute for Nuclear Research and Nuclear Energy, Sofia, Bulgaria
| | - B. Tseepeldorj
- Institute of Physics and Technology of the Mongolian Academy of Sciences, Ulaanbaatar, Mongolia
- Ulaanbaatar University, Ulaanbaatar, Mongolia
| | - A. Valkárová
- Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic
| | - C. Vallée
- Aix Marseille Université, CNRS/IN2P3, CPPM UMR 7346, 13288 Marseille, France
| | - P. Van Mechelen
- Inter-University Institute for High Energies ULB-VUB, Brussels and Universiteit Antwerpen, Antwerp, Belgium
| | - Y. Vazdik
- Lebedev Physical Institute, Moscow, Russia
| | - D. Wegener
- Institut für Physik, TU Dortmund, Dortmund, Germany
| | | | - J. Žáček
- Faculty of Mathematics and Physics, Charles University, Prague, Czech Republic
| | - Z. Zhang
- LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
| | | | | | - F. Zomer
- LAL, Université Paris-Sud, CNRS/IN2P3, Orsay, France
| |
Collapse
|
37
|
Abstract
Rheumatoid arthritis is the most common inflammatory rheumatic disease. Due to the destruction of joints in the course of the disease it leads to significant morbidity in affected patients. The quality of life and even life expectancy can be severely impaired. Early diagnosis and early initiation of treatment is a decisive step towards a more benign course of the disease. New classification criteria have been published in order to help in early diagnosis. Methods of imaging, such as ultrasound and magnetic resonance imaging help in the detection of synovitis, which is the major pathomorphological manifestation of arthritis and should be identified without any doubt. Treatment follows the rule of treat to target with the aim of achieving remission or if this is not realistic, at least the lowest possible level of disease activity. The first and perhaps most important step in therapy is the initiation of methotrexate or if contraindications are present, another disease-modifying antirheumatic drug (DMARD) as soon as the diagnosis is made. Initial addition of glucocorticoids is recommended, which should be reduced in dose and terminated as soon as possible. Furthermore, either the combination of different DMARDs or the start of biologic DMARDs, such as tumor necrosis factor alpha (TNF-alpha) inhibitors or second generation biologic DMARDs is possible as a treatment option. The treatment follows the rule of shared decision-making and is the standard to treat comorbidities, the use an interdisciplinary approach and to treat functional deficits by rehabilitation measures, such as physiotherapy.
Collapse
Affiliation(s)
- C Fiehn
- ACURA Rheumazentrum Baden-Baden, Rotenbachtalstr. 5, 76530, Baden-Baden, Deutschland.
| | - K Krüger
- Praxiszentrum St. Bonifatius, München, Deutschland
| |
Collapse
|
38
|
|
39
|
Krüger K, Bergerfurth A, Burger S, Pohl P, Wimmers M, Cleveland JC. Preparation, Conduct, and Experimental Results of the AVR Loss-of-Coolant Accident Simulation Test. NUCL SCI ENG 2017. [DOI: 10.13182/nse91-a15725] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Affiliation(s)
- K. Krüger
- Arbeitsgemeinschaft Versuchsreaktor AVR GmbH, Düsseldorf, Federal Republic of Germany
| | - A. Bergerfurth
- Arbeitsgemeinschaft Versuchsreaktor AVR GmbH, Düsseldorf, Federal Republic of Germany
| | - S. Burger
- Arbeitsgemeinschaft Versuchsreaktor AVR GmbH, Düsseldorf, Federal Republic of Germany
| | - P. Pohl
- Arbeitsgemeinschaft Versuchsreaktor AVR GmbH, Düsseldorf, Federal Republic of Germany
| | - M. Wimmers
- Arbeitsgemeinschaft Versuchsreaktor AVR GmbH, Düsseldorf, Federal Republic of Germany
| | | |
Collapse
|
40
|
Krüger K, Wik E, Knutsvik G, Nalwoga H, Klingen TA, Arnes JB, Chen Y, Mannelqvist M, Dimitrakopoulou K, Stefansson IM, Birkeland E, Aas T, Tobin NP, Jonassen I, Bergh J, Foulkes WD, Akslen LA. Expression of Nestin associates with BRCA1 mutations, a basal-like phenotype and aggressive breast cancer. Sci Rep 2017; 7:1089. [PMID: 28439082 PMCID: PMC5430803 DOI: 10.1038/s41598-017-00862-w] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/21/2016] [Accepted: 03/15/2017] [Indexed: 12/28/2022] Open
Abstract
We here examined whether Nestin, by protein and mRNA levels, could be a predictor of BRCA1 related breast cancer, a basal-like phenotype, and aggressive tumours. Immunohistochemical staining of Nestin was done in independent breast cancer hospital cohorts (Series I-V, total 1257 cases). Also, TCGA proteomic data (n = 103), mRNA microarray data from TCGA (n = 520), METABRIC (n = 1992), and 6 open access breast cancer datasets (n = 1908) were analysed. Patients with Nestin protein expression in tumour cells more often had BRCA1 germline mutations (OR 8.7, p < 0.0005, Series III), especially among younger patients (<40 years at diagnosis) (OR 16.5, p = 0.003). Nestin protein positivity, observed in 9–28% of our hospital cases (Series I-IV), was independently associated with reduced breast cancer specific survival (HR = 2.0, p = 0.035) and was consistently related to basal-like differentiation (by Cytokeratin 5, OR 8.7–13.8, p < 0.0005; P-cadherin OR 7.0–8.9, p < 0.0005; EGFR staining, OR 3.7–8.2, p ≤ 0.05). Nestin mRNA correlated significantly with Nestin protein expression (ρ = 0.6, p < 0.0005), and high levels were seen in the basal-like intrinsic subtype. Gene expression signalling pathways linked to high Nestin were explored, and revealed associations with stem-like tumour features. In summary, Nestin was strongly associated with germline BRCA1 related breast cancer, a basal-like phenotype, reduced survival, and stemness characteristics.
Collapse
Affiliation(s)
- Kristi Krüger
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, Section for Pathology, University of Bergen, Bergen, Norway
| | - Elisabeth Wik
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, Section for Pathology, University of Bergen, Bergen, Norway.,Department of Pathology, Haukeland University Hospital, Bergen, Norway
| | - Gøril Knutsvik
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, Section for Pathology, University of Bergen, Bergen, Norway.,Department of Pathology, Haukeland University Hospital, Bergen, Norway
| | - Hawa Nalwoga
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, Section for Pathology, University of Bergen, Bergen, Norway.,Department of Pathology, Makerere University College of Health Sciences, P. O. Box 7072, Kampala, Uganda
| | - Tor A Klingen
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, Section for Pathology, University of Bergen, Bergen, Norway.,Department of Pathology, Vestfold Hospital, Tønsberg, Norway
| | - Jarle B Arnes
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, Section for Pathology, University of Bergen, Bergen, Norway.,Department of Pathology, Haukeland University Hospital, Bergen, Norway
| | - Ying Chen
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, Section for Pathology, University of Bergen, Bergen, Norway.,Department of Pathology, Vestfold Hospital, Tønsberg, Norway.,Department of Pathology, Akershus University Hospital, Lørenskog, Norway
| | - Monica Mannelqvist
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, Section for Pathology, University of Bergen, Bergen, Norway
| | - Konstantina Dimitrakopoulou
- Centre for Cancer Biomarkers CCBIO and Computational Biology Unit, Department of Informatics, University of, Bergen, Norway
| | - Ingunn M Stefansson
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, Section for Pathology, University of Bergen, Bergen, Norway.,Department of Pathology, Haukeland University Hospital, Bergen, Norway
| | - Even Birkeland
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, Section for Pathology, University of Bergen, Bergen, Norway
| | - Turid Aas
- Department of Surgery, Haukeland University Hospital, Bergen, Norway
| | - Nicholas P Tobin
- Department of Oncology and Pathology, Karolinska Institute and University Hospital, Stockholm, Sweden
| | - Inge Jonassen
- Centre for Cancer Biomarkers CCBIO and Computational Biology Unit, Department of Informatics, University of, Bergen, Norway
| | - Jonas Bergh
- Department of Oncology and Pathology, Karolinska Institute and University Hospital, Stockholm, Sweden
| | - William D Foulkes
- Program in Cancer Genetics, Departments of Oncology and Human Genetics, McGill University, 546 Pine Avenue West, Montreal, QC, H2W 1S6, Canada
| | - Lars A Akslen
- Centre for Cancer Biomarkers CCBIO, Department of Clinical Medicine, Section for Pathology, University of Bergen, Bergen, Norway. .,Department of Pathology, Haukeland University Hospital, Bergen, Norway.
| |
Collapse
|
41
|
Abstract
Psoriatic arthritis is a chronic inflammatory disease of the musculoskeletal system with association to skin psoriasis and is characterized by variable clinical symptoms with very heterogeneous degrees of disease suffering for patients. Clinical manifestations essentially include alterations to the skin and nails, peripheral arthritis, enthesitis, dactylitis and/or spinal involvement. This variability necessitates an individualized therapy of patients with different therapy targets. Apart from international guidelines no therapy recommendations are available in Germany for treatment of psoriatic arthritis. For this reason this article summarizes the established points, characteristics and aspects to be considered in the therapy of psoriatic arthritis in Germany, taking the various main forms of the disease into consideration.
Collapse
Affiliation(s)
- F Behrens
- CIRI/Rheumatologie und Fraunhofer IME, Translationale Medizin und Pharmakologie, Universitätsklinikum Goethe Universität Frankfurt, Frankfurt am Main, Deutschland
| | - D Thaçi
- Exzellenzzentrum Entzündungsmedizin, UKSH - Campus Lübeck, Lübeck, Deutschland
| | - J Wollenhaupt
- Rheumatologikum Hamburg an der Schön Klinik Hamburg Eilbek, Dehnhaide 120, 22081, Hamburg, Deutschland.
| | - K Krüger
- Internistisch-rheumatologische Praxis, München, Deutschland
| |
Collapse
|
42
|
Kiltz U, Alten R, Fleck M, Krüger K, Manger B, Müller-Ladner U, Nüsslein H, Reuss-Borst M, Schwarting A, Schulze-Koops H, Tausche AK, Braun J. [Evidence-based recommendations for diagnostics and treatment of gouty arthritis in the specialist sector : S2e guidelines of the German Society of Rheumatology in cooperation with the AWMF]. Z Rheumatol 2017; 76:118-124. [PMID: 28078432 DOI: 10.1007/s00393-016-0249-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Due to the increasing prevalence of gout, particularly in old age, the disease is becoming of increasing importance in Germany. Gout is one of the most common forms of recurrent inflammatory arthritis and is induced by the deposition of monosodium urate crystals in synovial fluid and other tissues. The principal goals of therapy in chronic gout are the symptomatic treatment of the acute joint inflammation and the causal treatment of the underlying metabolic cause, the hyperuricemia. Only a consistent and permanent reduction of the serum uric acid level ultimately results in an efficient avoidance of further gout attacks and therefore the prevention of structural damage. Due to an often inadequate treatment of gout, the target of healing the disease is often not achieved. A correct and timely diagnosis and adequate assessment of comorbidities associated with gout are, however, of substantial importance for patient and physician to achieve remission of the disease. In order to create a solid basis for a timely and effective treatment of affected patients, in 2016 the German Society of Rheumatology (DGRh) initiated the development of S2e guidelines on gouty arthritis for specialists. This article summarizes these S2e guidelines on the management of gouty arthritis in the specialist sector.
Collapse
Affiliation(s)
- U Kiltz
- Rheumazentrum Ruhrgebiet, Claudiusstr. 45, 44649, Herne, Deutschland.
| | - R Alten
- Rheumatologie, Klinische Immunologie, Osteologie, Physikalische Therapie und Sportmedizin, Schlosspark-Klinik, Berlin, Deutschland
| | - M Fleck
- Klinik und Poliklinik für Innere Medizin I, Klinik für Rheumatologie/Klinische Immunologie, Asklepios-Klinikum, Uniklinikum Regensburg, Bad Abbach, Deutschland
| | - K Krüger
- Rheumatologisches Praxiszentrum St. Bonifatius, München, Deutschland
| | - B Manger
- Medizinische Klinik 3, Universitätsklinikum Erlangen, Erlangen, Deutschland
| | - U Müller-Ladner
- Abteilung für Rheumatologie und Klinische Immunologie, Kerckhoff-Klinik, Bad Nauheim, Deutschland
| | - H Nüsslein
- Rheumatologische Schwerpunktpraxis, Nürnberg, Deutschland
| | - M Reuss-Borst
- Facharzt-Praxis für Rheumatologie und Onkologie, Bad Bocklet, Deutschland
| | - A Schwarting
- Rheumatologisch-immunologische Ambulanz, Universitätsklinik Mainz, Mainz, Deutschland
| | | | - A K Tausche
- Medizinische Klinik III, Abteilung für Rheumatologie, Universitätsklinikum Carl Gustav Carus, Dresden, Deutschland
| | - J Braun
- Rheumazentrum Ruhrgebiet, Claudiusstr. 45, 44649, Herne, Deutschland
| |
Collapse
|
43
|
Büsing K, Berk A, Müller S, Kieckhäven S, Krüger K, Zeyner A. Comparison of calculated and experimentally determined SID of CP and AA in complex diets differing in AA contents for grower finisher pigs. J Anim Physiol Anim Nutr (Berl) 2017; 101:e297-e302. [DOI: 10.1111/jpn.12605] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2016] [Accepted: 08/21/2016] [Indexed: 01/19/2023]
Affiliation(s)
- K. Büsing
- Chair of Nutrition Physiology and Animal Nutrition; Faculty of Agricultural and Environmental Sciences; University of Rostock; Rostock Germany
| | - A. Berk
- Federal Research Institute for Animal Health; Institute of Animal Nutrition; Braunschweig Germany
| | - S. Müller
- Thuringian State Institute for Agriculture; Regional Office Bad Salzungen; Bad Salzungen Germany
| | - S. Kieckhäven
- Chair of Nutrition Physiology and Animal Nutrition; Faculty of Agricultural and Environmental Sciences; University of Rostock; Rostock Germany
| | - K. Krüger
- Evonik Industries AG; Isernhagen Germany
| | - A. Zeyner
- Institute for Agricultural and Nutritional Sciences, Group Animal Nutrition; Martin Luther University Halle-Wittenberg; Halle (Saale) Germany
| |
Collapse
|
44
|
Abstract
Cardiovascular (CV) events are among the most important comorbidities and are the major cause of death in inflammatory rheumatic diseases, such as rheumatoid arthritis (RA). Disease activity and traditional CV risk factors contribute to the total CV risk. Among the antirheumatic drugs used for long-term treatment of RA, non-steroidal anti-inflammatory drugs (NSAID) and glucocorticoids lead to an increased risk but disease-modifying antirheumatic drugs (DMARD), such as hydroxychloroquine, methotrexate and especially biologics significantly reduce the risk. Besides achieving the best possible disease control, rheumatologists should identify additional CV risk factors and also initiate adequate treatment in order to reduce or even eliminate the CV risk. When treating rheumatic diseases possible drug-induced elevation of CV risk must be considered. Finally, the CV risk should be regularly monitored.
Collapse
Affiliation(s)
- K Krüger
- Rheumatologisches Praxiszentrum, St. Bonifatius Str. 5, 81541, München, Deutschland.
| |
Collapse
|
45
|
Pilat C, Krüger K, Frech T, Mooren FC. Exercise-induced cytokine changes in antigen stimulated whole-blood cultures compared to serum. J Immunol Methods 2016; 440:58-66. [PMID: 27876507 DOI: 10.1016/j.jim.2016.11.007] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/22/2016] [Revised: 11/16/2016] [Accepted: 11/16/2016] [Indexed: 01/10/2023]
Abstract
Strenuous exercise is followed by an elevation of many cytokines with inflammation regulating properties. Since most cytokines act at pico- or nanomolar concentrations many investigations failed to detect their concentrations in vivo. Hence, the aim of this study was to evaluate the significance of cytokine measurements (IL-1β, TNF-α, IL-1ra, IL-6, CCL2 and CXCL8) in a stimulated whole-blood culture (sWBC) compared to serum with respect to their exercise-induced kinetics and detection rates. 40 male volunteers (age: 25,5±4,3years, BMI: 24,00±2,24, VO2peak: 46,9±4,1mL/kg×min) performed 60min of intensive bicycle exercise (80% VO2peak). Blood samples were taken before and for up to 24h after exercise. All cytokines were determined by a multiplex ELISA. There were weak to moderate correlations between cytokines in sWBC and serum. While exercise did not affect pro-inflammatory cytokines in serum, in sWBC only IL-1β was increased 1.2-fold at 3h (p<0,05). All other cytokines increased both in sWBC and serum. The detection rate was superior in sWBC vs serum for most cytokines. Exercise-induced cytokine kinetics in sWBC do not reflect systemic changes. Both approaches provide a synergistic insight into inflammatory processes on the cytokine level.
Collapse
Affiliation(s)
- C Pilat
- Department of Sports Medicine, Justus-Liebig-University, Kugelberg 62, 35394 Gießen, Germany.
| | - K Krüger
- Department of Sports Medicine, Justus-Liebig-University, Kugelberg 62, 35394 Gießen, Germany
| | - T Frech
- Department of Sports Medicine, Justus-Liebig-University, Kugelberg 62, 35394 Gießen, Germany
| | - F C Mooren
- Department of Sports Medicine, Justus-Liebig-University, Kugelberg 62, 35394 Gießen, Germany
| |
Collapse
|
46
|
Abstract
Mainly due to the general demographic changes and decreasing mortality in rheumatic diseases based on therapeutic progress, the proportion of older patients treated by rheumatologists is growing. Drug treatment in the elderly, however, harbors certain risks including age-specific pharmacokinetic features and high rates of multimorbidity and polypharmacy resulting in a risk of drug interactions and adherence problems. Nevertheless, older patients suffering from rheumatic diseases ought to be treated with the same intensity and same targets as the younger counterparts. Bearing all these facts in mind it is a balancing act for rheumatologists to find an optimal treatment for the individual elderly patient. Fear of risks should not lead to hesitant use of drugs leaving these patients alone with treatment deficits, as some studies have suggested.
Collapse
Affiliation(s)
- K Krüger
- Rheumatologisches Praxiszentrum, St. Bonifatius Str. 5, 81541, München, Deutschland.
| | - A Strangfeld
- Deutsches Rheuma-Forschungszentrum (DRFZ), Berlin, Deutschland
| | - C Kneitz
- Klinik für Innere Medizin II, Rheumatologie/Immunologie, Rheumazentrum, Klinikum Südstadt Rostock, Rostock, Deutschland
| |
Collapse
|
47
|
Krüger K, Walter U, Dreier M. Die Rolle der hausärztlichen Empfehlung bei der Inanspruchnahme einer Screening-Koloskopie. Gesundheitswesen 2016. [DOI: 10.1055/s-0036-1586696] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
48
|
Krüger K, Walter U, Dreier M. Risikogruppen für eine Passivrauchexposition in Deutschland – Analyse des Telefonsurveys GEDA 2012. Gesundheitswesen 2016. [DOI: 10.1055/s-0036-1586633] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
|
49
|
Riediger H, Krüger K, Makowiec F, Adam U, Krueger CM. [Symptoms, Diagnostics, Treatment and Classification of 22 Patients with Postpancreatectomy Haemorrhage (PPH) in a Series of 400 Consecutive Pancreatic Head Resections and Pancreatectomies]. Zentralbl Chir 2016; 141:616-624. [PMID: 27501072 DOI: 10.1055/s-0042-109978] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Introduction: Postpancreatectomy haemorrhage (PPH) is a dangerous complication after pancreatic resection. Patients and Methods: From 2006 to 2015, 400 consecutive pancreatic head resections and pancreatectomies were performed and prospectively documented. This study analysed incidence, treatment and outcome of patients with PPH. Results: Incidence of PPH was 5.5 % (n = 22). PPH occurred in a median of eight days after pancreatic surgery with an equal frequency of symptoms being caused by gastrointestinal bleeding (n = 11) and abdominal bleeding (n = 11). Postoperative pancreatic fistulas (POPF) were significantly more frequent in case of PPH (45 % POPF in case of PPH vs. 20 % POPF in case of no PPH, p < 0.01). PPH was more frequent after pancreatogastrostomy (8/70; 11 %) than after pancreatojejunostomy (11/281; 4 %; p = 0.01). The majority of bleedings after pancreatogastrostomy came from the intragastric cut surface of the pancreas. During the first week, relaparotomy was significantly more frequent (n = 5; 56 %) than in late PPH (n = 1; 8 %; p = 0.01). In late PPH, interventions (angiography; n = 7, endoscopy; n = 4) were more frequent. In 16 severe cases, surgical/interventional bleeding control (n = 12) or relevant transfusions of more than 3 units of packed red blood cells (n = 4) were performed. Compared with the whole group, mortality was significantly increased in case of PPH (13.6 % in case of PPH vs. 3.7 % in case of no PPH; p = 0.03). Conclusion: PPH is an episodic and potentially life-threatening complication with an increased mortality rate, which is frequently associated with impaired healing of the pancreatic anastomosis. Diagnostic investigation and treatment of PPH requires an experienced surgical centre with a close cooperation with endoscopy and (interventional) radiology.
Collapse
Affiliation(s)
- H Riediger
- Klinik für Chirurgie - Visceral- und Gefäßchirurgie, Humboldt-Klinikum, Berlin, Deutschland
| | - K Krüger
- Institut für Radiologie und Interventionelle Therapie, Humboldt-Klinikum, Berlin, Deutschland
| | - F Makowiec
- Klinik für Allgemein- und Viszeralchirurgie, Universitätsklinikum Freiburg, Deutschland
| | - U Adam
- Klinik für Chirurgie - Visceral- und Gefäßchirurgie, Humboldt-Klinikum, Berlin, Deutschland
| | - C M Krueger
- Klinik für Chirurgie - Visceral- und Gefäßchirurgie, Humboldt-Klinikum, Berlin, Deutschland
| |
Collapse
|
50
|
Krüger K, Wik E, Klingen TA, Chen Y, Aas T, Akslen LA. Abstract 3937: Nestin expression is associated with a basal-like phenotype and poor prognosis in breast cancer. Cancer Res 2016. [DOI: 10.1158/1538-7445.am2016-3937] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Background:
Nestin, neuroepitheilal stem cell protein, is an intermediate filament protein first described in neural stem or progenitor cells, and its expression has been seen in several tissues, including different types of cancer.
In breast cancer, Nestin expression has been linked to the triple negative and basal-like phenotypes. We here evaluated Nestin and its association with clinico-pathologic markers and survival in two prospective Norwegian breast cancer cohorts.
Materials and methods:
Series I includes 546 women (50-69 years) diagnosed with primary invasive breast cancer (403 screen-detected and 143 interval cancers) as part of the prospective and population-based Norwegian Breast Cancer Screening Program (NBCSP) during 1996-2003 (Hordaland county).
Series II includes 282 women (50-69 years) with invasive cancers (199 screen-detected and 83 interval cancers) diagnosed as part of the NBCSP during 2004-2009 (Vestfold County).
Immunohistochemical staining of Nestin was done on tissue microarrays (TMAs). Expression in tumor cells was graded by a Staining Index (SI) (values 0-9).
Results:
Nestin positivity, observed in 9% and 13% of the breast cancer cases in Series I and II, was associated with higher histological grade (OR, odds ratio 14.3 and 8.1), high tumor cell proliferation by Ki-67 (OR 11.4 and 9.1), larger tumor diameter (OR 1.8 and 2.4), but not with lymph node status or HER2 status. Further, Nestin positivity was associated with negativity for estrogen (OR 14.9 and 11.9) and progesterone receptor (8.5 and 3.4), the triple negative phenotype (OR 29.1 and 17.4) and basal-like differentiation by positivity for Cytokeratin 5 (OR 9.1 and 8.7) or P-cadherin (OR 7.0 and 8.5).
By univariate survival analysis, Nestin positivity was associated with reduced breast cancer specific (p = 0.002 and p = 0.076) and overall survival (p = 0.005 and p = 0.039). When including the standard variables tumor size, histologic grade and lymph node status in a multivariate analysis, Nestin was still significantly associated with reduced breast cancer specific survival in the largest cohort (Series I).
Conclusion:
We found that Nestin expression in breast cancer is associated with aggressive features, the triple negative phenotype, basal-like differentiation, and reduced breast cancer specific survival.
Citation Format: Kristi Krüger, Elisabeth Wik, Tor Audun Klingen, Ying Chen, Turid Aas, Lars A. Akslen. Nestin expression is associated with a basal-like phenotype and poor prognosis in breast cancer. [abstract]. In: Proceedings of the 107th Annual Meeting of the American Association for Cancer Research; 2016 Apr 16-20; New Orleans, LA. Philadelphia (PA): AACR; Cancer Res 2016;76(14 Suppl):Abstract nr 3937.
Collapse
Affiliation(s)
- Kristi Krüger
- 1Centre for Cancer Biomarkers, CCBIO, Department of Clinical Medicine, University of Bergen, Bergen, Norway
| | - Elisabeth Wik
- 1Centre for Cancer Biomarkers, CCBIO, Department of Clinical Medicine, University of Bergen, Bergen, Norway
| | | | - Ying Chen
- 3Department of Pathology, Akershus University Hospital, Lørenskog, Norway
| | - Turid Aas
- 4Department of Surgery, Haukeland University Hospital, Bergen, Norway
| | - Lars A. Akslen
- 1Centre for Cancer Biomarkers, CCBIO, Department of Clinical Medicine, University of Bergen, Bergen, Norway
| |
Collapse
|